1(91)   
 Drug Substance   Dapagliflozin  
 Study Number  ISS Number  ESR-15-11724  
 Version Number   3.3 
 Date  Day Month Year   
10/03 /2017 
   
   
 
 Study Title:  Dapagliflozin and M easures of Cardiovascular Autonomic 
Function in Patients with Type 2 Diabetes (T2D ) 
 
TITLE PAGE   
Sponsor:  AstraZeneca  
 
 [STUDY_ID_REMOVED]  
 
 
 
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
2(91) TABLE OF CONTENTS  PAGE  
TITLE PAGE  ................................ ................................ ................................ ...........  1 
TABLE OF CONTENTS  ................................ ................................ .........................  2 
LIST OF ABBREVIATIONS AND DEFINITION OF TE RMS  ............................  6 
1. INTRODUCTION  ................................ ................................ ................................ ... 9 
1.1 Background  ................................ ................................ ................................ ..............  9 
1.2 Research hypothesis  ................................ ................................ ...............................  10 
1.3 Rationale for conducting this study  ................................ ................................ ....... 10 
1.4 Benefit/risk and ethical assessment ................................ ................................ ........  11 
2. STUDY OBJECTIVES  ................................ ................................ ..........................  13 
2.1 Prima ry objective  ................................ ................................ ................................ ... 13 
2.2 Secondary objectives  ................................ ................................ .............................  13 
2.3 Safety objective  ................................ ................................ ................................ ...... 13 
2.4 Exploratory objectives  ................................ ................................ ...........................  14 
3. STUDY PLAN AND PROCE DURES  ................................ ................................ .. 14 
3.1 Overall study design and flow chart  ................................ ................................ ...... 14 
3.2 Rationale for study design, doses and control groups  ................................ ............  17 
4. SUBJECT SELECTION CR ITERIA  ................................ ................................ .... 17 
4.1 Inclusion criteria  ................................ ................................ ................................ .... 17 
4.2 Exclusion criteria  ................................ ................................ ................................ ... 18 
5. STUDY CONDUCT  ................................ ................................ ..............................  19 
5.1 Restrictions during the study  ................................ ................................ .................  19 
5.2 Subject enrollment and randomization and initiation of  investigational 
product  ................................ ................................ ................................ ...................  19 
5.2.1  Procedures for randomization  ................................ ................................ ................  19           
5.2.2        Study Visits  ................................ ................................ ................................ ............  20 
5.2.3        Assessments  ................................ ................................ ................................ ...........  23 
5.3 Procedures for handling subjects incorrectly enrolled   or randomized  or 
initia ted on investigational product  ................................ ................................ ........  24 
5.4 Blinding and procedures for unblinding the study  ................................ .................  25 
5.4.1  Methods for ensuring bl inding  ................................ ................................ ...............  25 
5.4.2  Methods for unblinding the study  ................................ ................................ ..........  25 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
3(91) 5.5 Treatments  ................................ ................................ ................................ ..............  25 
5.5.1  Identity of investigational product(s)  ................................ ................................ ..... 25 
5.5.2  Doses and treatment regimens  ................................ ................................ ...............  25 
5.5.3  Additional study drug  ................................ ................................ ............................  25 
5.5.4  Labeling  ................................ ................................ ................................ .................  26 
5.5.5  Storage  ................................ ................................ ................................ ...................  26 
5.6 Concomitant and post -study tre atment(s)  ................................ ..............................  26 
5.7 Treatment compliance  ................................ ................................ ............................  26 
5.7.1  Accountability  ................................ ................................ ................................ ........  27 
5.8 Discontinuation of investigational product  ................................ ............................  27 
5.8.1  Procedures for discontinuation of a subject from investigational product  ............  27 
5.9 Withdrawal from study  ................................ ................................ ..........................  27 
6. COLLECTION OF STUDY VARIABL ES ................................ ...........................  28 
6.1 Recording of data  ................................ ................................ ................................ ... 29 
6.2 Data collection at enrol lment and follow -up ................................ .........................  29 
6.2.1  Enrollment procedures  ................................ ................................ ...........................  29 
6.2.2  Follow -up procedures  ................................ ................................ ............................  30 
6.3 Efficacy  ................................ ................................ ................................ ..................  30 
6.3.1  Efficacy variable  ................................ ................................ ................................ .... 30 
6.4 Safety  ................................ ................................ ................................ .....................  30 
6.4.1  Definition of adverse events  ................................ ................................ ..................  30 
6.4.2  Definitions of serious adverse event  ................................ ................................ ...... 31 
6.4.3  Recording of adverse events  ................................ ................................ ..................  31 
6.4.4  Reporting of serious adverse events ................................ ................................ ....... 33 
6.4.5  Laboratory safety assessment  ................................ ................................ ................  34 
6.4.6  Physical examination  ................................ ................................ .............................  34 
6.4.7  ECG  ................................ ................................ ................................ ........................  34 
6.4.7.1  Resting 12 -lead ECG  ................................ ................................ .............................  35 
6.4.7.2  Real time display (telemet ry) ................................ ................................ .................  35 
6.4.8  Vital signs  ................................ ................................ ................................ ..............  35 
6.4.8.1  Pulse and blood pressure  ................................ ................................ ........................  35 
6.4.8.2  Body temperature  ................................ ................................ ................................ ... 35 
6.4.9  Other safety assessments  ................................ ................................ ........................  35 
6.5 Patient reported outcomes (PRO)  ................................ ................................ ..........  35 
6.5.1.1  Name of PRO method or questionnaire  ................................ ................................ . 35 
6.6 Pharmacokinetics  ................................ ................................ ................................ ... 35 
6.6.1  Collection of samples  ................................ ................................ .............................  37 
6.6.2  Determination of drug concentration  ................................ ................................ ..... 37 
6.7 Pharmacodynamics  ................................ ................................ ................................  37 
6.7.1  Collection of pharmacodynamic markers  ................................ ..............................  38 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
4(91) 6.8 Pharmacogenetics  ................................ ................................ ................................ .. 38 
6.8.1  Collection of pharmacogenetic samples  ................................ ................................  38 
6.9 Health economics  ................................ ................................ ................................ ... 38 
7. BIOLOGICAL SAMPLING PROCEDURES  ................................ .......................  38 
7.1 Volume of blood  ................................ ................................ ................................ .... 38 
7.2 Handling, storage and destruction of biological samples  ................................ ...... 38 
7.2.1  Pharmacokinetic and/or pharmacodynamic samples  ................................ .............  39 
7.2.2  Pharmacogenetic samples  ................................ ................................ ......................  39 
7.3 Labeling and shipment of biohazard samples  ................................ ........................  39 
7.4 Chain of custody of biol ogical samples  ................................ ................................ . 39 
7.5 Withdrawal of informed consent for donated biological samples  .........................  39 
8. ETHICAL AND REGULATO RY REQUIREMENTS  ................................ .........  39 
8.1 Ethical conduct of the study  ................................ ................................ ...................  39 
8.2 Ethics and regulatory review ................................ ................................ ..................  39 
8.3 Informed consent  ................................ ................................ ................................ ... 39 
8.4 Changes to the protocol and  informed consent form  ................................ .............  40 
8.5 Audits and inspections  ................................ ................................ ...........................  40 
9. STUDY MANAGEMENT  ................................ ................................ ....................  40 
9.1 Training of study site personnel  ................................ ................................ .............  40 
9.2 Monitoring of the study  ................................ ................................ .........................  41 
9.2.1  Source data  ................................ ................................ ................................ .............  41 
9.3 Study timetable and end of study  ................................ ................................ ...........  41 
10. DATA MANAGEMENT  ................................ ................................ .......................  41 
11. EVALUATION AND CAL CULATION OF VARIABLE S ................................ . 42 
11.1  Calculation or derivation of efficacy variable(s)  ................................ ...................  42 
11.2  Calculation or derivation of safety variable(s)  ................................ .......................  42 
11.2.1  Other significant adverse events (OAE)  ................................ ................................  42 
11.3  Calculation or derivation of patient reported outcome variables  ...........................  42 
11.4  Calculation or derivation of pharmacokinetic variables  ................................ ........  42 
11.5  Calculation or derivation of pharmacodynamic variable(s)  ................................ ... 42 
11.5.1  Calculation or derivation of the relationship between pharmacokinetic and 
pharmacodynamic variables  ................................ ................................ ...................  42 
11.5.2  Populat ion analysis of pharmacokinetic/pharmacodynamic variables  ..................  42 
11.6  Calculation or derivation of pharmacogenetic variables ................................ ........  43 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
5(91) 11.7  Calculation or derivation of health economic variables ................................ .........  43 
12. STATISTICAL METHODS AND SAMPLE SIZE DETE RMINATION  ............  43 
12.1  Descrip tion of analysis sets  ................................ ................................ ....................  43 
12.1.1  Efficacy analysis set  ................................ ................................ ...............................  43 
12.1.2  Safety analysis set  ................................ ................................ ................................ .. 43 
12.2  Methods of statistical analyses  ................................ ................................ ...............  43 
12.2.1  Interim analyses  ................................ ................................ ................................ ..... 44 
12.3  Determination of sample size  ................................ ................................ .................  44 
12.4  Data monitoring committee  ................................ ................................ ...................  45 
13. IMPORTANT MEDICAL PR OCEDURE S TO BE FOLLOWED BY THE 
INVESTIGATOR  ................................ ................................ ................................ .. 46 
13.1  Overdose  ................................ ................................ ................................ ................  46 
13.2  Pregnancy  ................................ ................................ ................................ ...............  47 
13.2.1  Maternal exposure  ................................ ................................ ................................ .. 47 
13.2.2  Paternal exposure  ................................ ................................ ................................ ... 47 
14. LIST OF REFERENCES  ................................ ................................ .......................  48 
 
LIST OF TABLES  
Table 1: Proposed scheduled visits  
LIST OF FIGURES  
Figure 1: Study  Design  
LIST OF APPENDICES  
 Appendix:  Case report forms ( Medical History and Physical Examination, Concomitant 
Medications  Worksheet, Cardiovascula r Autonomic Neuropathy Testing Worksheet , Heart 
Rate Variability Test  Report, Adverse Events Reporting Form, Instructions for  Patients for 
Heart Rate Variability Testing , Routine  Visit Case Report Form , ECG Report, and 
Glucometer Download Data ) 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
6(91) LIST OF ABBREVIATION S AND DEFINITION OF TERMS  
The following abbreviations and special terms are used in this study Clinical Study Protoc ol. 
Abbreviation or  
special term                               Explanation  
  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
7(91) Abbreviation or  
special term                               Explanation  
T1D 
T2D 
CAN  
CVD  
DDP -4 
SGLT -2 
CV  
FDA  
HR 
BP 
RR 
AE 
HRV  
CARTs  
IRB 
LV 
BNP  
ADA  
ULN  
PAD  
MI 
BMI  
SBP 
DBP  
CBCP  
CMP  
HbA1c  
TSH  
ECHO  
ESC 
ECG  
AST  
ALT  
CRF  
MEND  
LF 
HF 
E/I ratio  
 Type 1 diabetes  
Type 2 diabetes  
Cardiovascular  autonomic  neuropathy  
Cardiovascular disease  
Dipeptidyl -peptidase -4  
Sodium -glucose transporter -2  
Cardiovascular  
Food and drug a dministration  
Heart rate  
Blood pressure  
Relative risk  
Adverse event  
Heart rate variability  
Cardiovascular autonomic reflex  tests 
Institutional  review board  
Left ventricle  
B type natriuretic peptide  
American Diabetes Association  
Upper limit of normal  
Peripheral arterial disease  
Myocardial infarct  
Body mass index  
Systolic blood pressure  
Diastolic blo od pressure  
Complete blood count with platelet  
Complete metabolic panel  
Hemoglobin A1c  
Thyroid stimulating hormone  
Echocardiogram  
Electrochemical skin conductance  
Electrocardiography  
Aspartate aminotransferase  
Alanine aminotransferase  
Case report form  
Meta bolism , Endocrinology and Diabetes Division  
Low frequency  
High frequency  
Expiration/ inspiration ratio  
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
8(91) Abbreviation or  
special term                               Explanation  
SDNN  
rmsSD  
EDV  
ESV  
CO 
TNFα  
IL1β  
IL6 
MCP -1 
IL8 
IL17  
m-CSF 
sVCAM -1 
s-ICAM -1 
IL10  
SAE  Standard deviation of the normal RR interval  
Root mean square of th e differences of successive RR intervals  
End diastolic volume  
End systolic volume  
Cardiac output  
Tumor necrotic factor -alpha  
Interleukin 1 beta  
Interleukin 6  
Monocyte chemoattractant protein -1 
Interleukin 8  
Interleukin 17  
Macrophage colony -stimulating fa ctor  
Soluble vascular cell adhesion molecule -1 
Soluble intercellular adhesion molecule -1 
Interleukin 10  
Serious adverse  event  
HDL  
LDL  
ID 
RCR  
MICHR  High -density lipoprotein  
Low-density lipoprotein  
Identification  
Responsible conduct of research  
Michigan I nstitutes for clinical and Heath research  
RHR  
FBG  
CGM  Resting heart rate  
Fasting blood glucose  
Continu ous glucose monitoring  
MACE  
CV 
SD 
LBGI  
AUC  Mean amplitude of glycemic excursions  
Coefficient of variation  
Standard deviation  
Low blood glucose index   
Area under the curve  
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
9(91) 1. INTRODUCTION  
1.1 Background  
Diabetes mellitus contributes substantially to the global burden of disease, with an 
estimated 415 million people affected worldwide in 2015, and expected to increase to 6 42 
million by 2040 ( http://www.diabe tesatlas.org/ ). The majority of these cases are due to t ype 2 
diabetes (T2D) . The burden of T2D is driven by health care costs associated wit h disease 
management, its progressive course, the high prevalence and risks of chronic complications  
including diab etic kidney disease, retinopathy, neuropathy and cardiovascular disease  (CVD)  
(http://www.diabetesatlas.org/) , and the overall impact on patients’ quality of life [1].  
Currently , there are multiple FDA -approved agents  to treat hyperglycemia in patients 
with T2D , that include  metformin, sulfonylurea s, dipeptidyl -peptidase -4 (DPP -4) inhibitor s, 
glinides, thiazolidinedione s, insulin, glucagon  like peptide receptor agonist s, and most 
recently the sodium -glucose transporter -2 (SGLT -2) inhibitor s. These all have been  shown to 
have various degrees of  effective ness in promoting glucose lowering  in T2D  [2-6].  
The SGLT -2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) reduce 
hyperglycemia by selective inhibition of glucose reabsorption in renal proximal tubules via 
sodium -glucose co -transporter 2, an d have been approved by FDA as a monotherapy or in 
combination with other glucose lowering agents in patients with T2D for improvement of 
glycemic control with a low risk of hypoglycemia  
(http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204629s000lbl.pdf ; 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204042s002 lbl.pdf ; 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202293s003lbl.pdf )  [3-6],while 
also promot ing reductions in body weight and blood pressure (BP) [7, 8]. Potential 
mechanisms for BP reduction involve several pathways including a modest diuretic effect and 
weight reduction [9, 10]. In addition, recently reported human data suggest that the BP 
reduction with the SGLT -2 inhibitors may also be associated with an improvement in arterial 
stiffness via reductions in insulin dose and improved arterial compliance, a direct effects on 
vascular smooth muscle relaxation after induction of a negative sodium balance, and a 
suppression of markers of inflammation a nd fibrosis, including nuclear factor κβ and c ollagen 
IV expression [11].  One interesting obs ervation is that reduction in systolic and diastolic BP 
with SGLT -2 inhibitors occurred without a compe nsatory increase in HR [3, 11, 12] and that 
most benefit was obtained also in patients with so me evidence of heart failure [12]. 
Tighter  glucose control ha s been shown to effectively prevent chronic complications 
(nephropathy, retinopathy, neuropathy )[13, 14] and CVD in patients with an early course of 
T2D on metformin treatment arm  [15, 16]. However , in patients with more advanced disease, 
the ef fects of tight glucose control on preventing CVD were inconsistent [17-19]. In addition, 
the effects of the specific agents used to treat hyperglycemia on the chronic complications and 
especially on CVD events in T2D remain uncertain , with some agents showing some potential 
benefit [15, 20] while most had been neutral  [13, 21-23].  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
10(91) However, most recently beneficial effect s on CV D events  were reported with a SGLT -
2 inhibitor, empagliflozin , in patients with T2D  at high risk of CVD events  [12]. The 
Empagliflozin: Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients 
(EMPA -REG OUTCOME) trial, a randomized double -blind placebo -controlled trial, reported 
significant reduction of death from card iovascular cause (38% RR), all -cause mortality (32% 
RR) and hospitalization for heart failure (35% RR) in patients with T2D  in em pagliflozin 
treatment arms [12].  
The exact mec hanism s of the beneficial effects on cardiovascular outcomes is not yet 
understood, although their effects on body weight, glucose control and blood pressure (BP) 
reduction were suggested [7, 10, 12]. 
1.2 Research hypothesis  
We hypothesize  that the potential benefits of SGLT -2 inhibitors on cardiovascular 
outcomes in pa tients with T2D are due to modulatory effects on the  
sympathetic/parasympathetic imbala nce, and cardiovascular autonomic neuropathy (CAN) as 
suggested by a blunting in the expected compensatory increase in HR associated with BP 
lowering.  
1.3 Rationale for cond ucting this study  
As mentioned above reduction  in systolic and diastolic BP with SGLT -2 inhibitors 
occur without a compe nsatory increase in HR [3, 11, 12]. In addition, in the EMPA -REG trial  
the CVD outcome was driven by a reduction in CVD  related death and most b enefit was 
observed  in patients wi th evidence of heart  failure [12]. Although glucose control, reduction 
in BP and weight loss have all been considered for beneficial effects o nCVD, other classes of 
above agents also reduce glucos e, BP, and some body weight, while similar effects o n CVD 
were not reported  [23], except for the recent report  of Liraglutide and Cardiovascular 
Outcomes in Type 2 Diabetes  [24]. 
Thus, to test  the above hypothesis we plan to evaluate potential mechanisms that could 
explain the CVD benefits with SGLT -2 inhibitor s. We plan to specifically test  in this study 
whether these benefits may be due to changes in  the sympathetic/parasympathetic function 
and thus protect against arrhythmia and /or progression of myocardial  dysfunction.  We plan to 
perform a  randomized, single -blinded to the investigators, open -label , 2-period crossover 
phase IV  clinical trial compar ing 12 -weeks of glycemic intervention with a  SGLT2 inhibitor , 
dapagliflozin versus a sulfonylurea , glimepiride  on measures of heart rate variability ( HRV) . 
The rationale for using an active comparator is to maintain similar levels of glucose control 
with t he interventions and thus accou nt for the effects of reduction  in blood glucose on 
measures of CAN, and the current evidence demonstrates similar glucose lowering  effects 
between S GLT2 inhibitors and sulfonylurea s [25]. In addition, sulfonylurea s are very 
commonly used in treating T2D in clinical practice. Given some potential detrimental CVD  
effects described with glyburi de or glipizide [26, 27], we have elected to use glimepiride  in 
this study  to evaluate the changes in measures of CAN durin g these different interventions . 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
11(91)  We also plan to  evaluate the indices of glucose variability and its association  with 
changes in CAN parameters in patients with type 2 diabetes during each dapagliflozin and 
glimepiride treatment period. Glucose variability is also associated with an increased risk of 
hypoglycemia, which is an important barrier in sustaining intensive treatment in patients with 
diabetes  [28, 29]. Recurrent severe hypoglycem ia, besides inducing alterations in cardiac 
electrical stability and QT interval prolongation, may contribute to alter the cardiac autonomic 
function and the cardiovagal balance, increasing the risk of cardiac arrhythmia in patients with 
diabetes  [30, 31] Theoretically, given the higher propensity for hypoglycemia, sulfonylurea 
may induce more glycemic variabili ty than SGLT -2 inhibitors. Currently no studies evaluated 
directly the changes in daily glucose excursions with these commonly prescribed agents were 
done. Thus, adding a component continuous glucose monitoring with the Abbott’s Freestyle 
Libre Pro for 2 w eeks during each sulfonylurea and SGLT -2 inhibitor intervention phase in 
this T2D cohort, will enable performing additional analyses linking effects of medications on 
daily glucose profiles with measures of heart rate variability and heart function, that c ould 
unveil important data on CVD risk with a minimal additional cost.  
.    
1.4 Benefit/risk and ethical assessment  
 
1.4.1 Risks Associated with Study Participation  
Risks associated with study participation in general are related to the time commitment 
for th e study, and risk for loss of privacy. There will be nine “in -person” visits required for the 
study. The study staff will try to minimize the burden of the visits to the extent practical by 
scheduling on days and at times that are most convenient for the p atient. Privacy risks will be 
reduced by maintaining a separate research record that uses a coded identifier, ra ther than 
personal identities. Links to the coded identifier and personal identity shall be maintained in a 
secure electronic file by the study coordinator and the links will ultimately be destroyed.  
Destruction of the links will occur no sooner than 2 years after the study has been 
acknowledged as terminated by the Univer sity of Michigan Institutional Review Board (UM 
IRB). 
1.4.2 Risks Associate d with Blood Collection  
Risks associated with blood collection are pain, discomfort, bleeding, bruising or 
infection. There is also the risk of dizziness, light -headedness, nausea or even fainting.   Blood 
sampling will be performed by staff with skill and  experience in venipuncture.  
1.4.3 Risks Associated with Study Medications  
The study medications, dapagliflozin and glimepiride, are very effective in glucose 
lowering. However,  because of glucose lowering agents, they are also associated with 
hypoglycemia  in general. However,  because of the mechanism of action of dapagliflozin 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
12(91) (SGLT -2 inhibitor), the risk of hypoglycemic  episodes is considered to be low. The 
recommended starting dose of dapagliflozin is 5 mg  daily and glimepiride 1 -2 mg daily. 
Therefore,  we will start with low dose and titrate it up to optimal dose (dapagliflozin 10 mg 
daily and glimepiride 4 mg daily) based on participants’ glucose monitoring and control to 
minimize  hypoglycemic episodes. Symptoms attributed to hypoglycemia  as well as gluc ose 
levels will be closely monitored in the trial.  
Other  potential risks of dapagliflozin  are volume depletion, diabetes ketoacidosis, 
urinary tract and genital infection and hypotension. Subjects will be advised to maintain 
adequate fluid intake and moni tor BP closely during study periods. If the study participant 
develops any of the mentioned risks, he/she will be managed and monitored according to 
standard care.  
The common potential side  effects of FDA approved glimepiride  are hyperse nsitivity 
reaction  and gastrointestinal reactions. All participants will be notified of risks of the study 
medications and are required to report to us as soon as they notice. The study personnel will 
report all directly observed adverse events and all adverse events sponta neously reported by 
the trial subject to University of Michigan IRB  as adverse event s (AE)  and record those in 
CRF.  All pati ents participating in this study  will be treated in accordance to best sta ndard of 
care per  American Diabetes Association guidelines  and recommendations.  
All the participants will receive both study medications equally (12 -week intervention 
period) in certain order. Both the study medications are proved to be effective in lowering 
glucose. In addition, the patients taking  part in the trial may derive general medical benefit 
from careful and close monitoring by medical personnel during the study. Safety will be 
ensured by monitoring the subjects for AEs both clinically and by laboratory testing and by 
the home blood glucose monitoring. Participation in the study is completely voluntary and the 
participant can withdraw  anytime from the study if one does not want to continue study 
medications either due to adverse events or other reasons. The study will potentially benefit to 
the diabetes society as it will reveal the important information regarding the potential 
mechanism of dapagliflozin (SGLT -2 inhibitor) on sympathetic/parasympathetic tone, and this 
may further contribute to the potential benefits on cardiovascular outcomes in patients with 
diabetes.  
1.4.4 Risk  Associated with Cardiovascular Autonomic Testing  
Participants will be asked to fast in preparation for testing and are therefore at risk  for 
hypoglycemia. Testing will be scheduled in the morning to shorten the duration of fastin g.  
The test itself has few risks associated with it, although some patients may become dizzy or 
lightheaded when moving from supine to standing, or after performing Valsalva  maneuvers. 
Subjects will be reminded to report any dizziness or lightheadedness i mmediately to the 
examiner and will be instructed to return to a seated or lying position as needed to relieve 
symptoms.   
1.4.5 Risk  Associated with Wearing Continuous Glucose Monitoring  Device  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
13(91)   Participants will be  provided with a Freestyle Libre Pro CG M for mon itoring of 
interstitial glucose every 5 -minute in terval for 14 days during each study intervention phase. 
There is a  very low risk for developing a local skin infection at the site of the sensor needle 
placement. Itchiness, redness, bleeding, and bruising at the insertion site may occur as well as 
local tape allergies.  
 During follow -up visit, the site where a CGM sensor has been worn will be carefully 
assessed by study personnel.  
2. STUDY OBJECTIVES     
   The main objective of this study is to evaluate the effects  of dapagliflozin vs active 
comparator , glimepiride  on meas ures of CAN,  and indirectly on CVD  outcomes in patients 
with T2D.   
2.1 Primary objective  
  Evaluate the effects of 12-week  treatment with dapagliflozin  5 mg daily escalating to 
10 mg d aily on measures of CAN  as assessed by changes in HRV, changes in cardiovascular 
autonomic reflex tests (CARTs) and resting heart rate  (RHR)  compared with 12-week  
treatment with glimepiride  2 mg daily escalating the dose to 4 mg (no more than 4 mg daily)  
as needed based on glucose monitoring and control.  
2.2 Secondary objectives : 
              Evaluate the e ffects of 12 -week glycemic interventions on glucose control,  BP, and 
weight .  
2.3 Safety objective :  
Evaluate  the following parameters:  
1. Incidence of symptomati c and asymptomatic hypoglycemia , glucose ≤ 70 mg/dl , as 
defined by American Diabetes Association (ADA)  
2. Incidence of sever hypoglycemia as defined by hypoglycemia requiring assistance  
from another person. It is also characterized by cognitive impairment tha t may be 
recognized  or unrecognized and can progress to loss of consciousness, seizure, coma, 
or death, and it is reversed by administration of glucose.  
 
3. UTIs  
4. Any other AEs  (see Section 1.4)  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
14(91) 2.4 Exploratory  objectives  
We will e valuate the effects of dapagliflo zin on measures of cardiac function . We w ill 
assess  the B type natriuretic peptide (BNP), a sensitive biomarker for left  ventricle function 
and  prognosis and risk stratification  [32, 33] at baselines and 12 weeks after each study drug 
(2 periods) .  
We will use a 14 -day continuous  glucose monitoring (CGM) using Abbott ’s Freestyle  
Libre Pro to evaluate and compar e the indices of glucose variability [ mean  glucose , standard 
deviation (SD), coefficient of variation (CV) , the mean amplitude of glycemic excursions 
(MAGE ), low blood glucose index (LBGI ) and area under the curve  (AUC) for 
hypoglycemia]  during each dapagl iflozin and glimepiride intervention phase in patients with 
type 2 diabetes and also assess the association between the indices of glucose variability and 
changes in measures o f HRV during each intervention period .  
3. STUDY PLAN AND PROCE DURES  
3.1 Overall study design and flow chart  
This is a 26 -week, single -center, randomized, single -blinded to the investigators, open -
label , 2-period crossover phase IV clinical trial comparing 12 -weeks of glycemic intervention 
with dapagliflozin versus glimepiride  on measures of  HRV . The two periods will be separated 
by a 2 -week wash -out period. All subjects will be allocated and randomized to each treatment 
sequence in a 1:1 fashion. Participants wi ll receive either dapagliflozin 5 mg or glimepiride 2 
mg daily initially for 4 we eks then titrating the dose gradually  up to dapagliflozin 10 mg daily 
or glimepiride 4 mg daily  (no more than 4 mg daily)  as needed based on glucose monitoring 
for 8 more weeks (total 12 weeks) followed by 2 -week washout period . Then they  will receive 
the study drugs in reverse order to the first period for another 12 weeks. Glucose  variability 
will be also assessed using Abbott ’s Freestyle  Libre Pro CGM  for 2 -week during  each 
intervention period.  
 
 
 
 
 
 
 
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
15(91) Figure 1: Proposed study design  
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
16(91) Table 1 : Proposed visit schedule  
 
  Period 1  Wash
-out Period 2  
Visit Numbers  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5   Visit 6  Visit 7  Visit 8  Visit 9  
Visit Description  Screening  Baseline 
Visit 
(Study 
Drug  1) Monitoring  Monitorin
g End of 
Study 
Drug 1 N/A Baselin e 
Visit 
(Study 
Drug 2 ) Monitoring  Monitoring  End of 
Study 
Drug 2 
Time point  Day -30 to 
0 Day 0  Week 4  Week 8  Week 
12 Week 
13-14 Week 15  Week 19  Week 23  Week 26  
Visit window  1 month  ± 7 days  ± 7 days  ± 7 days  ± 7 
days  NA ± 7 days  ± 7 days  ± 7 days  ± 7 day s 
Informed consent 
and HIPPA1 X          
Medical history  X    X  X   X 
Physical exam2 X    X     X 
Inclusion/Exclusion 
criteria  X          
Concomitant 
medications  X      X    
Vital signs  X X X X X  X X X X 
Urine analysis , 
urine β -HCG test in 
women of 
childbearing age  X          
Venous blood A1C  X    X     X 
CBC P, FBG, 
comprehensive 
metabolic profile, ,  
lipid profile , and 
urine albumin 
excretion  X    X     X 
TSH X          
BNP  X    X  X   X 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
17(91) ECG  X    X  X   X 
HRV   X   X  X   X 
CARTs   X   X  X   X 
CGM     2 weeks       2 weeks    
Assess  
hypoglycemia   X X X X  X X X X 
Record Adverse 
Events (AEs), 
Serious Adverse 
Events (SAEs)   X X X X   X X X 
Assessment of 
compliance by 
counting pills    X X X   X X X 
1 The informed co nsent form must be signed before any study procedure is performed.  
2 Physical exams will include vital signs, height and weight measurements, as well as comprehensive systematic 
examination.   
 
3.2 Rationale for study design, doses and control groups  
 See abov e (section 1.3)  regarding  overall study design and comparator group.  
The dose titration algorithm descri bed above was selected to target equal glycemic  
lowering effects for avoiding confounding effects and for ethical considerations. To prevent 
hypoglycemi c episodes , we will initiate a lower dose for both study medications 
(dapagliflozin 5 mg and glimepiride 2 mg), and will escalat e the dose gradually up to 10 mg 
dapagliflozin and  glimepiride 4 mg daily  (no more than 4 mg daily)  as needed based on daily 
glucose monitoring and profile of AEs 
(http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202293s003lbl.pdf ).  
4. SUBJECT SELECTION CR ITERIA  
   We plan to enroll 45 subjects with type 2 diabetes mellitus (T2D) in this study  (see 
below power calculation) with the following eligibility criteria.  
 
4.1 Inclusion criteria  
1. Patients with type 2 diabetes as defined [34] on background metformin monotherapy 
who are not meeting ADA standard of care recommended glucose target [34] 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
18(91) 2. Age ≥18 years  
 
4.2 Exclusion criteria  
Subjects should not enter the study if any of the following exclusion criteria are fulfilled:  
1. History of recurrent  urinary tract infections  
2. Patients with mycotic infections especially genital infection.  
3. Severely hypote nsive patients   
4. History of unexplained microscopic or gross hematuria, or microscopic hematuria at 
visit 1, confirmed by a follow -up sample  
5. Presence of hypersensitivity to dapagliflozin or other SGLT2 inhibitors (e.g. 
anaphylaxis, angioedema, exfoliative  skin conditions ) 
6. Inability or refusal to comply with protocol  
7. Current participation or participation in an experimental drug study in previous 
three months  
8. Presence of history of diabetic ketoacidosis  
9. Planned cardiac surgery or angioplasty within 3 month s 
10. Recent history of acute CV events such as MI, stroke, PAD within 3 months prior to 
enrollment  
11. Patients with severe renal impairment or unstable or rapidly progressing renal 
disease or end stage renal disease.  
12. Clinical conditions that could interfere with  the cardiovascular autonomic function 
and heart rate variability (arrhythmias)  
13. Severe hepatic insufficiency and/or significant abnormal liver function (defined as 
aspartate aminotransferase >3× upper limit of normal (ULN) and/or alanine 
aminotransferase >3× ULN) or creatinine kinase >3× ULN.  
14. History of cancer other than basal cell carcinoma and or treatment for cancer within 
the last 5 years  
15. Women of child -bearing potential who may be pregnant or lactating.  
16. History of pancreas, kidney or liver transplant . 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
19(91) 17. History of drug or alcohol abuse  within 5 years  
18. History of allergy to sulfa drugs  
19. Presence of any condition that, in the opinion of the investigator would make it 
unlikely for the subject to complete the study.  
20. Congestive heart failure (CHF) defined as N ew York Heart Association class III 
and IV 
 
5. STUDY CONDUCT  
5.1 Restrictions during the study  
 All consented study patients are required to comply with the study protocol. 
Participation in other interventional  research studies is comple tely restricted to partici pants.  
Glycemic  intervention with additional antidiabetic  medications oth er than metformin is 
prohibited . See above exclusion criteria  in section 4.2.  
Medications that can interfere with the study procedures such as beta blockers, weight 
loss medications  etc. are restricted during the study  due to their influence on procedures for 
cardiovascular autonomic function . Systemic  steroids are also prohibited due to the influence 
on glucose metabolism.  
Participants  are also required to fast overnight the day befor e CAN testing  and blood 
draw. Women  of child -bearing potential must continue to practice an acceptable method of 
birth control throughout the study periods.  
5.2 Subject enro llment and randomi zation  and initiation of  
investigational product  
5.2.1 Procedures for rando mization  
 Subjects wi ll be proceeded  to visit 2 -baseline visit ( study drug 1 ) after they pass the 
screening visit (visit 1).   
Randomization to dapagliflozin or glimepiride:  After signing informed consent, 
confirming eligibility and completion of baseline assessments (visit 2), subjects will be 
randomized in a 1: 1 fashion to either open -label dapagliflozin 5 mg daily or open -label 
glimepiride 2 mg daily for 4 weeks and escalate the dose gradually up to dapagliflozin 10 mg 
daily or glimepiride 4 mg daily (no more than 4 mg daily) as needed based on their glucose 
monitoring. Patients will be aske d to check glucose in the morning and before dinner . Fasting 
glucose should be between 80 -130 mg/dl and daytime glucose should be in the range of 80 -
160 mg/dl.  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
20(91) Proced ure for Subject Treatment Assignment:  Subjects will be randomized  to 
treatment with either dapagliflozin or glimepiride. The procedures for randomization will be 
determined by the study biostatistician. The study drugs will be dispensed by the research 
pharmacy . 
5.2.2 Study Visits  
 The schedule of study visits is shown in Table 1. After obtaining informed consent, 
verifying eligibility at screening and completing all required ba seline assessments, subjects 
will be randomized and provided with  study medications. Patients will be also  followed every 
4 weeks in each study drug period. The staff should query the subject regarding any changes 
to their health, changes to their medication regimen , and frequen cy and severity of 
hypoglycemia at each visit.  
Visit 1: Screeni ng/Eligibility (Day -30 to 0)   
An eligibility visit will be scheduled for subjects who, based on preliminary screening 
(telephone, email, medical chart review) , meet the general entry criteria (re fer to inclusion 
criteria). At V isit 1 the investigator or h er designee will obtain written informed consent, after 
which all required eligibility examinations will be performed. The eligibility examination will 
include the foll owing laboratory assessments: Hemoglobin A1c (HbA1c) , comprehensive 
metabolic panel (CMP ) including FBG , complete blood count with platelets (CBCP), thyroid 
stimulating hor mone (TSH), lipid profile, B type  natriuretic peptide (BNP), urine albumin 
assessment, urine analysis and in all women of child bearing age and potential, a urine 
pregnancy  test, even if an accepted method of contraception is being used. If any of the 
required laboratory measures are documented in the subject’s medical record as being 
completed in the prior 3 months (1 month for HbA1c, and 6 months for urine albumin), they 
will not need to be repeated at the screening visit.  
Weight, height and seated blood pressure and pulse will be obtained.  A structured 
history and physical examination and electrocardiogram will be performed at the screening 
visit. All visit 1 measures are  to be completed at one visit.  
Visit 2 - Baseline Visit (Study Drug 1 ) (Day 0)  
This study w ill include  CAN  assessments (see section 5.2.3), meter download for 
evaluation of hypoglycemia at baseline and to initiate treatment with either dapagliflozin or 
glimepiride.  
Upon satisfactory completion of all eligibility and baseline visit (study drug  1) 
assessment, a 12 -week supply of dapagliflozin 5 mg tablet or glimepiride 2 mg tablet will be 
provided, and written instructions for use of the medication reviewed with and provided to the 
subject. Subjects will be instructed to take dapagliflozin  5 mg daily  or glimepiride 2 mg daily 
with or without food in the morning once daily for 4 weeks then escalating the dose up  to 
dapagliflozin 10 mg daily or glimepiride 4 mg  (no more than 4 mg daily) as needed based on 
glucose monitoring and control. Participants will be instructed to monitor glucose 2 times 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
21(91) daily, fasting glucose and before dinner with the goal of fasting glucose between 80 -130 mg/dl 
and of pre -meal gl ucose between 80 -180 mg/dl. Participants  will be asked to record glucose 
data and the number of doses taken every day on a log that will be provided. Participants  will 
be also asked to bring a glucometer with them for each visit. Subjects are to be reminded to 
return any unused study medication at their next visit. Adverse events will be recorded and 
reported as required.  
Study staff will contact the subject within one week of the Visit 2 to assess medication 
compliance and tolerance.  
All subjects in group A and  B will be allocated and randomized to each treatment 
sequence in a 1:1 fashion. Participants will receive either  dapagliflozin 5 mg or glimepiride 2 
mg daily initially for 4 weeks then titrating the dose based on blood glucose levels up  to 
dapagliflozin 1 0 mg daily or glimepiride 4 mg (no more than 4 mg daily) for 8 more weeks 
(total 12 weeks) followed by a 2-week washout period . Participants  will then receive the study 
drugs in reverse order to the first  study  drug period during second crossover period fo r another 
12 weeks.  
Visit 3: Safety Monitoring (Study Drug 1 ) (Week 4)  
At this visit, the study staff will obtain vital signs ( weight, blood pressure, resting heart 
rate) and will ask the subject about any changes in health status or physical symptoms and  
record the findings in the source documents. Glucometers will be downloade d and incidence 
of hypoglycemia will be evaluated. The staff will assess compliance with study drug and 
tolerance. Adverse events will be reco rded and reported as require d.  
Visit 4 : Safety Monitoring (Study Drug 1 ) (Week 8)   
At this visit, the study staff will obtain vital signs (weight, blood pressure, resting heart 
rate) and will ask the subject about any changes in health status or physical symptoms and 
record the findings in the  source documents. Glucometers will be downloade d and incidence 
of hypoglycemia will be evaluated. The staff will assess compliance with  study drug and 
tolerance. Adverse events will be rec orded and reported as required.  Urine pregnancy testing 
may be perf ormed at the discretion of the investigator for all women of childbearing potential.   
Participant s will be provided with  a Freestyle Libre Pro CGM to collec t glucose data 
for 2 week s following  this visit.  Libre Pro CGM will be placed on the participants b y trained 
study personnel during this visit. Freestyle Libre Pro CGM is very simple to use and does n ot 
require glucose calibration  or partici pant’s operation. Then participants will also be asked 
either to mail the CGM or to bring the CGM with them in nex t visit.  
Visit 5: End of Study Drug 1 (Week 12)  
At this visit, the  following will be per formed: vital signs (weight, blood pressure, 
resting heart rate), a structured history and physical examination , electrocardiogram , 
information about any adverse event s, all CAN assessment s (see section 5.2.3 ), meter 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
22(91) download for evaluation of hypoglycemia, blood draw for HbA1c, BNP , and safety laboratory 
assessments (CMP  including FBG , CBCP , urine albumin assessment and lipid profile ). The 
study staff will collect any unused study medication. The number of unused dapagliflozin or 
glimepiride tablets will be recorded in the source document and unused medication secured 
until returned for final drug disposition. During this visit, the site where a CGM sensor has 
been worn  will be carefully assessed by study personnel.  
Wash -out period  
 A 2-week wash -out period will be followed after first study drug period.  
Visit 6: Baseline Visit ( Study Drug 2) (Week 15)  
At this visit, the following will be performed : vital signs (weigh t, blood pressure, 
resting heart rate), a structured history , information about any adverse events, 
electrocardiogram, all CAN assessments (see section 5.2.3), meter download for evaluation of 
hypoglycemia  and blood  draw for BNP. The key activity of  this v isit is to re-initiate treatment 
with either dapagliflozin or glimepiride. After a 2 -week wash -out period, visit 6-baseline visit 
(study drug 2) will be initiated . Participants will again receive study  drugs (dapagliflozin or  
glimepiride) in a r everse orde r to the first study drug period  for another 12 weeks. Urine 
pregnancy testing may be performed at the discretion of the investigator for all women of 
childbearing potential.   
A 12 -week supply of dapagliflozin 5 mg tablet or glimepiride 2 mg tablet will b e 
provided, and written instructions for use of the medication reviewed with and provided to the 
subject. Subjects will be instructed to take dapagliflozin 5 mg or glimepiride 2 mg with or 
without food in the morning daily for 4 weeks then escalating to dapagliflozin 10 mg daily or 
glimepiride 4 mg (no more than 4 mg daily) as needed based on glucose monitoring and 
control . Participants  will be asked to record the number of doses taken every day on a log that 
will be provided. Subjects are to be reminded to  return any unused study medication at their 
next visit.  
Study staff will contact the subject within one week of the Visit 6 to assess medication 
compliance and tolerance.  
Visit 7: Safety Monitoring  (Study Drug 2)  (Week 19)  
At this visit, the study staff  will obtain vital signs (weight, blood pressure, resting heart 
rate) and will ask the subject about any changes in health status or physical symptoms and 
record the findings in the source documents. Glucometers will be downloade d and incidence 
of hypoglyc emia  will be evaluated. The staff will assess compliance with  study drug and 
tolerance. Adverse events will be recorded and reported as required.  
Visit 8: Safety Monitoring  (Study Drug 2)  (Week 23)  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
23(91) At this visit, the study staff will obtain vital signs (we ight, blood pressure, resting heart 
rate) and will ask the subject about any changes in health status or physical symptoms and 
record the findings in the source documents. Glucometers will be downloade d and incidence 
of hypoglycemia will be evaluated. The staff will assess compliance with study drug and 
tolerance. Adverse events will be recorded and reported as required. Urine pregnancy testing 
may be performed at the discretion of the investigator for all women of childbearing potential.  
 Participants will  be provided with a Freestyle Libre Pro CGM to col lect glucose data 
for 2 weeks following  this visit.  A Libre Pro CGM will be placed on the participants by 
trained study personnel during this visit. Freestyle Libre Pro CGM is very simple to use and 
does no t require glucose calibration or participant’s operation. Then participants will also be 
asked either to mail the CGM or to bring the CGM with them in next visit.  
Visit 9: End of Study Drug 2 (Week 26) or Final Visit  
At this visit, the following will be performed : vital signs (weight, blood pressure, 
resting heart rate), a structured history and physical examination, information about any 
adverse events, electrocardiogram, all CAN assessments (see section 5.2.3 ), meter download 
for evaluation of hypoglycem ia, blood draw for HbA1c, BNP, and safety laboratory 
assessments (CMP  including FBG , CBCP , urine albumin assessment and lipid p rofile ). The 
study staff will collect any unused study medication. The number of unused dapagliflozin or 
glimepiride tablets will  be recorded in the source document and unused medication secured 
until returned for final drug disposition.  
The study staff will collect any unused study medication. The number of unused 
dapagliflozin or glimepiride tablets will be recorded in the source  document and unused 
medication secured until returned for final drug disposition. The subjects will be again 
assessed for adverse events.  
During this visit, the site where a CGM sensor has been worn will be carefully 
assessed by study personnel.  
Within 1 week of the final visit, the study staff will contact the subject by phone or 
email to inquire about any changes in health status.  
5.2.3 Assessments  
CAN  
A. Heart rate variability (HRV) studies: low and high frequency power (LF,HF), and time 
domain measures of  HRV, standard deviation of normal RR interval(SDNN), root mean 
square of successive RR intervals (RMSSD) are analyzed from continuous ECG recordings 
using the ANX 3.1 software (ANSAR Inc., Philadelphia , PA) as described  [35, 36]. 
B. Cardiovascular reflex tests will include: 1) changes in R -R interval with deep breathing, 
a measure of sinus arrhythmia during qu iet respiration reflecting primarily parasympathetic 
function; 2) the R -R response to standing, inducing reflex tachycardia followed by 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
24(91) bradycardia which is jointly vagal and baroreflex -mediated; 3) the Valsalva ratio which 
evaluates cardiovagal function i n response to a standardized increase in intrathoracic pressure 
(Valsalva Maneuver); and  4) orthostatic changes in BP.  These tests are reproducible and 
considered as gold -standard  [36, 37]. 
C. Resting heart rate  
Subjects will be  asked to avoid  food,  caffeine and tobacco products for at least 8 hours 
prior to te sting, and hold any medication until testing was com pleted. Subjects who 
experienced a hypoglycemic episode after midnight [blood glucose ≤ 50mg/dl (2.77mmol/l)] 
prior to the testing were rescheduled.      
Cardiac function  
We w ill measure serum BNP, by Chemiluminescent Immunoassay (CLIA)  (Siemens, 
Erlangen , Germany) and will evaluate changes in BNP, as a biomarker for LV function. The 
blood draw will be performed at baseline and end of each study drug period.  
Assessment of glucose variability  
  We will use a 14 -day continuous  glucose monitoring (CGM) using Ab bott’s Freestyle 
Libre Pro to evaluate and compare the indices of glucose variability [mean glucose, standard 
deviation (SD), coefficient of variation (CV), the mean amplitude  of glycemic excursions 
(MAGE) , low blood glucose index (LBGI) and area under the  curve (AUC) for 
hypoglycemia] during each dapagliflozin and glimepiride intervention phase in patients with 
type 2 diabetes and also assess the association between the indices of glucose variability and 
changes in measures of HRV during each intervention period.  
 
5.3 Procedures for handli ng subjects incorrectly enrolled  or 
randomi zed or initiated on investigational product  
 The data management plan for this project is based on the randomization of 45 
participants, with randomization occurring at the time of V isit 2. All candidates who complete 
the informed consent proces s will be assigned a study identification number (ID) at the time of 
Visit 1. Unless otherwise stipu lated by the sponsor -investigator , the ID numbers  are patient -
specific and will be retained a nd associated with  candidates who fail screening or are found to 
be ineligible, and/ or drop -out prior to randomization. Follow -up will not be continued for 
candidates who do not proceed to randomization.  Follow -up and research activities will be 
pursued o n all randomized participants, even those candidates who may for some reason stop 
research medications.   
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
25(91) 5.4 Blinding and procedures for unblinding the study  
5.4.1 Methods for ensuring blinding  
The investigators will be blinded to the study drugs. The research phar macy and 
participants will know the  study drugs  that participants will be on . The research  pharmacy will 
be dispensing the study medicat ions per the randomization schedule  that will be provided by 
the study biostatistician .  
5.4.2 Methods for unblinding the stud y 
 In the event of an emergency and a need to know study medications, the investigator 
will contact the Research Pharmacist and request identification of subject’s test article 
assignment. The Research Pharmacist will indicate that the blind was broken on the Pharmacy 
Randomization Log and will document the date of the request, the name of the research 
personnel making the request, and the pharmacist’s signature. The research coordinator will 
report the emergent event on the Adverse Event CRF and the unmask ing event on the 
Unmasking Report CRF and then signed by the investigator.   
5.5 Treatments  
5.5.1 Identity of investigational product(s)  
 Dapagliflozin 5 mg tablet  
Dapagliflozin is a sodium glucose trasporter -2 (SGLT -2) inhibitor, a new class of 
glucose lowering age nt that reduces hyperglycemia in patients with T2D by reducing renal 
glucose reabsorption.  
Investigational product  Dosage form and strength  Manufacturer  
Dapagliflozin  
Glimepiride  5 mg tablet  
1 mg tablet  AstraZeneca  
Sanofi Aventis  
   
 
5.5.2 Doses and treat ment regimens  
  Participants will receive either  open -label  dapagliflozin 5 mg or open -label glimepiride 
2 mg daily  initially for 4 weeks then titrating the dose based on blood glucose levels up to 
dapagliflozin 10 mg daily or glimepiride 4 mg (no more tha n 4 mg daily)  daily for 8 more 
weeks (total 12 weeks) followed by a 2-week washout period and then participants  will 
receive the study drugs in reverse order to the first period for another 12 weeks.  
5.5.3 Additional study drug  
 Glimepiride 2 mg tablet  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
26(91) Glimepiri de is a sulfonylurea agent that reduces hyperglycemia in patients with T2D 
by stimulating insulin release from the pancreatic beta cells and reduction of glucose output 
from the live r. 
5.5.4 Labeling  
The label will include the following information:  trial number , medication  number.  
Each medication box will contain an appropriate amount of dapagliflozin  or 
glimepiride tablets, plus some reserve, for dosing until the next scheduled visit. Study drug 
will be supplied on a per Visit basis. Supply will be managed by  University of Michigan  
Health System (UMHS)  research pharmacy.  
 
5.5.5 Storage  
 Dapagliflozin film -coated tablets  and glimepiride tablets should be stored at 15° to 
25°C (59° to 77°F) in a tightly closed container.  The minimum/ maximum storage temperature 
must b e measured and documented at least weekly by investigational drug store manager or 
pharmacist. All study medications wi ll be contained in medication bo xes identified with the 
trial number and medication number.    
 
5.6 Concomitant and post -study treatment(s)  
 The research staff will record all concomitant drugs used by the subject  in the source 
documents. This is to include prescription, non -prescription, homeopathic medications and 
dietary/vitamin supplements.  At the screening visit, medication use is to be ca refully 
reviewed to ensure that no contraindicated medications as described in the protocol are being 
used (e.g., beta blocker agents, phentermine).  At all subsequent visits, subjects will be asked 
to report any changes to their reported medication use an d the source document updated 
accordingly.  Queries regarding medication exclusions and contraindications are directed to 
the study principle investigator.  
5.7 Treatment compliance  
 Study staff will contact the subjec t within one week of initiating  study medi cations  to 
assess medication compliance and tolerance . All patien ts will be asked to bring their study 
medications with them to each study visit. The study staff will assess medication compliance 
and tolerance  at each visit .  Patients will be reminded abou t purpose of the s tudy and 
importance of compliance with the study medications  at each visit. Adverse events will be 
similarly recorded and reported as required. The study staff will also collect any unused study 
medication  at the end of each intervention period . The number of unused dapagliflozin or 
glimepiride tablets will be recorded in the source document and unused medication secured 
until returned for final drug disposition.  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
27(91) 5.7.1 Accountability  
  The pharmacist / investigational drug storage manager must maintain records of the 
trial medication’s delivery to the trial site, the inventory at the site, the use by each patient, 
and destruction of  unused medication . Proof of destruction will be provided to AstraZeneca at 
the end of the study . These records wil l include dates, quantities, batch/serial numbers, expiry 
(‘use by’) dates, and the unique code numbers assigned to the investigational product and trial 
patients. The pharmacist / investigational drug storage manager will maintain records that 
document ad equately that the patients were provided the d oses specified by the study protocol  
and reconcile all investigational product s.  
5.8 Discontinuation of investigational product  
  The study drugs will be discontinued in the following conditions:  
1. Study patient wit hdraws consent.  
2. Study patient fails to comply with the study protocol.  
3. Study subject becomes pregnant . 
4. If the study patient will need to be on conco mitant drugs that may interfere with the 
study findings or study medications  that may lead to higher risk of  hypoglycemia, the 
study medication can be discontinued.  
5. If the  study patient develops persistent or recurrent serious side effects as described 
above (Section 1.4 , 6.4.2 and 6.4.4 ), study drugs will be discontinued perman ently. 
 
5.8.1 Procedures for discontinua tion of a subject from investigational product  
  If the study patient withdraws consent  or wh o fails  to comply with the study protocol 
or becomes pregnant , participation in the study will end and the study medication will  be 
stopped. No further ev aluation will be performed and no attempts should be made to collect 
additional data.   
 If a patient develops UTI or genital infection, we will manage the infection according 
to standard of care. However,  a patient with persistent  or recurrent UTI or genital infec tion 
despite standard of care , study medications will be hold temporarily until infections resolve. If 
a patient develops persistent  serious adverse effects from study drugs ( section 6.4.2 and 6.4.4 ), 
study medications will be discontinued permanently. And  patients will be followed up until 
their serious adverse effects are completely resolved.  
5.9 Withdrawal from study  
  A subject may withdraw from the trial at any time at their own request, or they may 
be withdrawn at any time at the discretion of the investi gator for safety, behavioral, or 
Clinical Study Protocol  
Drug Substance Dapaglif lozin  
 
28(91) administrative reasons.  If a subject does not return for a scheduled visit, every effort should 
be made to contact the subject.  In any circumstance, every effort should be made to document 
subject outcome, if possible.   
If the subject withdraws consent, no further evaluations should be performed and no 
attempts should be made to collect additional data; however, they may be questioned 
regarding their reason for withdrawal and asked to return all unused investigational pro ducts.  
Patients who withdraw or discontin ue from the trial after randomiz ation will not be 
replaced.  
6. COLLECTION OF STUDY VARIABLES  
   We will collect the following variables for primary and secondary endpoints:  
Primary En dpoints:  
Changes in measures of HR V as defined by: Frequency domain measures of HRV 
(continuous variables): high frequency (HF) power (0.04 -0.15 Hz) (ms2); low frequency (LF) 
power (0.15 -0.4 Hz) (ms2) as measured by the LF:HF ratio. The primary outcome will be the 
difference of the LF:HF r atio from baseline to 12 weeks between the two drugs (periods).  
 Secondary Endpoints:  
1) Changes in mea sures of HRV as defined by: T ime domain measures of HRV (continuous 
variables): ( i) standard deviation of the normal RR interval (SDNN) (msec) and (ii) root mean 
square of the differences of successive RR intervals (rmsSD) (msec)  
2) Changes in CARTs as defined by: i) expiration/inspiration (E/I) ratio, ii) Valsalva ratio and 
iii) 30:15 ratio  
3) Changes in BNP with each intervention as a measure LV functio n 
 Exploratory Endpoints:  
1) Evaluate the indices of glucose variability (mean, SD, CV, MACE, LBGI, AUC for 
hypoglycemia)  during  each intervention period  
2) Assess the association  between the indices of glucose variability and changes in measures 
of CAN p arameters during each intervention phase  
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
29(91) 6.1 Recording of data  
  Case Report Forms (CRFs) for individual patients will be developed  by the 
investigator s and served as the source document. Source documents provide evidence for the 
existence of the patient and substantiate the int egrity of the data collected. The study staff  will 
record all medical history, physical examination, safety laboratory assessment  and all 
procedures involved during the study in CRF. Principle investigator will review, sign and date 
the results. The study staff will communicate with the patients regarding their results and 
appropriate follow -up and management.  It is the  sponsor - investigator's responsibility to 
ensure accuracy, completeness, legibility, and timeliness of the data report ed.  Data reported 
in the CRF, that are derived from source documents, should be consistent with the source 
documents or the discrepancies  will be explained by the study staff. Any change or correction 
to a CRF will be d ated, initialled, and explained by t he study staff.  
6.2 Data collection at enrol lment and follow -up 
  The following data will be collected at enrollment  periods (for each study drug 
period) : 
1. Vital signs: BP, weight, BMI, HR  
2. Blood sam ple for safety laboratory asse ssments , glucose control a nd biomarker for cardiac 
function (CBC P, CMP including  FBG , HbA1c , lipid panel and urine albumin assessment , 
BNP ) (See Table 1)  
3. ECG s for heart rate variability  studies  (LF, HF, LF/HF ratio, SDNN and RMSSD) , 
cardiovascular autonomic reflex tests  (E/I rat ion, Valsalva  ratio, 30:15  and orth ostatic BP ) and 
RHR  
4. Asses sment of hypogl ycemia by evaluating symptoms and downloading  glucometers  and 
glucose log sheets  
         During follow -up monitoring visits, we will assess hypog lycemi a (sympt oms, 
recordings)  vital signs, any changes in their medication list, recording of adverse events, 
serious adverse events and compliance and tolerability  of study medications.  
         At the end of each interv ention period, we will repeat the same measures and procedures 
to obtain primary and secondary en dpoints. Those include blood sam ple fo r biomarkers, HRV, 
and CARTs . 
          We will also evaluate the indices of glucose variability by using Freestyle Libre Pro 
CGM during each intervention phase in this cohort.  
6.2.1 Enrol lment procedures  
  All candidates will be selected from University of Michigan  Health System (UMHS ), 
which  has a unified electronic medical records system (EPIC) that allows screening in real 
time for all patients seen at UMHS via best practice alerts. Curren tly there are ~ 25,000 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
30(91) patients with type 2 diabetes that are being seen in our system. In addition, we have access to 
the Diabetes  Registry,  an IRB approved registry of patients with diabetes who provided 
written consent to have their medical records scre ened to determine eligibility and to be 
contacted directly should they be eligible.  
 Once identified , the candid ates will be contacted via phone or email and provided the 
information regarding the study. Following their review of the study , candidates  who express 
interest in participation will be scheduled for a screening visit (visit 1) in the dedicated 
research space either  within the outpatient clinics of the Division of Metabolism, 
Endocrinology and Diabetes (MEND) or at the Michigan Clinical Research U nit. (MCRU) 
(http://www.michr.umich.edu/services/mcru ) depending on subjects preferences.  
 Once eligibility is confirmed , candidates will proceed to Visit 2 -baseline visit  within 4 
weeks for randomiz ation and dispensing study medication. Written instructions for use of the 
medication will be reviewed with and provided to the subject.  All partic ipants will be asked 
to monitor glucose in the mornin g and before dinner and record in the log book  and mete r.   
6.2.2 Follow -up procedures   
 Follow -up monitoring visit will be scheduled every 4 weeks during intervention 
period. After randomization visit (V isit 2), the study staff will contact the subject within one 
week via phone  to assess medic ation compliance and t olerance.  Participants  will be asked to 
record the number of doses taken every day on a log that will be provided. All partic ipants 
will also be asked to monitor glucose in the morning and before dinner , and record  those in 
the log book. Participants  will be advi sed to bring the study medications, glucometers and 
glucose log books at each follow -up visit. Depending on glucose monitoring and their 
tolerability, the dose of study medications will be doubled in following visit (V isit 3). Subjects 
are to be rem inded to return any unused study medication at their next visit.  
6.3 Efficacy : NA 
 
6.3.1 Efficacy variable :  NA 
 
6.4 Safety  
 The Principal Investigator is responsible for ensuring that all staff involved in the 
study is familiar with the content of this section.  
6.4.1 Defini tion of adverse events   
 An adverse event is the development of an undesirable medical condition or the 
deterioration of a pre -existing medical condition following or during exposure to a 
pharmaceutical product, whether or not considered causally related t o the product.  An 
undesirable medical condition can be symptoms (e .g., nausea, chest pain), signs (e .g., 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
31(91) tachycardia, enlarged liver) or the abnormal results of an investigation (e .g., laboratory 
findings, electrocardiogram).  In clinical studies, an AE c an include an undesirable medical 
condition occurring at any time, including washout period , even if no study treatment has been 
administered.  
The term AE is used to include both serious and non -serious AEs.  
6.4.2 Definitions of serious adverse event  
A serious a dverse event is an AE occurring during any study phase (i .e., treatment, washout, 
follow -up), that fulfils one or more of the following criteria:  
 Results in death  
 Is immediately life -threatening  
 Requires in -patient hospitali zation or prolongation of existi ng hospitali zation  
 Results in persistent or significant disability/incapacity or substantial disruption of 
the ability to conduct normal life functions  
 Is a congenital abnormality or birth defect  
 Is an important medical event that may jeopardi ze the subje ct or may require 
medical intervention to prevent one of the outcomes listed above.  
The causality of SAEs (their relationship to all study treatment/procedures) will be 
assessed by the investigator(s) and communicated to AstraZeneca.  
6.4.3 Recording of adverse e vents  
 
The investigator s are responsible  to perform periodic and special assessments for 
adverse events.  All adverse events w ill be summarized and reported  to the Institutional 
Review Board.  The investigator and research staff will note all AEs  reported  by the s ubject 
after administration of d apagliflozin or glimepiride .  All clinical complaints volunteered by, or 
elicited from, the subject during the study will be recorded in the appropriate section of the 
case report form for the study period indicated.   AEs may include events that occur as a result 
of protocol -mandated procedures (e.g., events due to invasive procedures). We will only 
include non -invasive proced ures such as HRV and CARTs for assessment of cardiovascular 
autonomic  function. Therefore,  AEs from protocol -mandated procedures are not likely 
expected other than minor skin irr itation from elec trodes.  If any AE occurs, the subject will 
receive appropriate treatment and medical supervision and will be followed until the AE is 
stabilized or to a p oint where it is no longer clinically significant.  As previously noted, all 
medical conditions and abnormal findings present before administration of t he first dose of 
dapagliflozin or glimepiride will be recorded as concurrent illnesses or baseline sympt oms.  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
32(91)  Follow -up of unresolved adverse events: All AEs judged to be clinically significant, 
including clinically significant laboratory abnormalities, will be followed until resolution. The 
following variables will be collected for each AE:  
 AE (verbatim)  
 The date and time  when the AE started and stopped  
 Whether the AE is serious or not (that is, the intensity – mild, moderate or severe)  
 Investigator causality rating against the Investigational Product or procedures 
(unlikely, possibly, probably, definitely)  
 Action taken with regard to investigational product/procedure  
 Adverse event caused  subject’s withdrawal from study (yes or no ) 
 Outcome (recovered, recovering, ongoing, fatal – see SAE).  
In addition, the following variables will be collected for serious adv erse events:  
 Date AE met criteria for serious AE  
 Date Investigator became aware of serious AE  
 AE is serious due to:  
 Date of hospitalization  
 Date of discharge  
 Probable cause of death  
 Date of death  
 Autopsy performed  
 Causality assessment in relation to study procedure(s)  
 Causality assessment in relation to other medication  
 Causality assessment in relation to additional study drug  
 Description of AE.  
 Date reported to IRB  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
33(91) It is important to distinguish between serious and severe AEs.  Severity is a measure of 
intensity whereas seriousness is defined by the criteria in Section 6.4.2 .  An AE of severe 
intensity need not necessarily be considered serious.  For example, nausea that persists for 
several hours may be consider ed severe nausea, but not a SAE. On the other hand, a stroke 
that results in only a limited degree of disability may be considered a mild stroke but would be 
a SAE.  
 Adverse Events based on signs and symptoms:  When collecting AEs, the recording 
of diagnose s is preferred (when possible) to recording a list of signs and symptoms.  However, 
if a diagnosis is known and there are other signs or symptoms that are not generally part of the 
diagnosis, the diagnosis and each sign or symptom will be recorded separate ly. 
 Adverse Events based on examinations and tests:  Deterioration as compared to 
baseline in protocol -mandated glucose values and/or blood pressure values should therefore 
only be reported as AEs if they fulfil  any of the SAE criteria or are the reason fo r 
discontinuation of treatment with the investigational product.  
If deterioration in glucose concentration and/or blood pressure is associated with 
clinical signs and symptoms, the sign or symptom will be reported as an AE and the 
associated laboratory res ult/vital sign will be considered as additional information.  Wherever 
possible the reporting investigator uses the clinical, rath er than the laboratory term (e.g. , 
anemia versus low hemoglobin value). In the absence of clinical signs or symptoms, clinical ly 
relevant deteriorations in non -mandated parameters should be reported as AE(s).  
Any new or aggravated clinically relevant abnormal medical finding at a physical 
examination as compared with the baseline assessment will be reported as an AE.  
 Repo rting o f serious adverse events : Investigators must inform the FDA, via a Med 
Watch /AdEERs form, of any serious or unexpected adverse events that occur in accordance 
with the reporting obligations of 21 CFR 312.32, and will concurrently forward all such 
reports t o AstraZeneca  within 24 hours of events .  A copy of the Med Watch /AdEERs report 
must be faxed to AstraZeneca at the time the event is reported to the FDA.  It is the 
responsibility of the investigator to compile all necessary information and ensure that th e FDA 
receives a report according to the FDA reporting requirement timelines and to ensure that 
these reports are also submitted to AstraZeneca at the same time.  
When reporting to AstraZeneca, a cover page  should accompany the Med Watch /AdEERs  
form indicat ing the following:  
 Investigator Sponsored Study (ISS)  
 The investigator’s name and address  
 The trial name/title and AstraZeneca ISS reference number  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
34(91) Investigative site must also indicate, either in the SAE report or the cover page, the causality  
of events in relation to all study medications  and if the SAE is related to disease progression , 
as determined by the principal investigator.  
The study staff will s end SAE report and accompanying cover page by way of fax to 
AstraZeneca’s designated fax line: 1 -1-302-886-4114 or email 
AEMailboxClinicalTrialTCS@astrazeneca.com  within 24 hours of events.  
Serious adverse events  that do not require expedited reporting to the FDA need to be 
reported to AstraZe neca preferably using the MedDRA coding language for serious adverse 
events.   
The investigator will contact the research pharmacist and request a copy of the 
randomization code to identify the subject with SAE for expedited reporting  to IRB. The 
research pharmacist will indicate that the blind was broken on the Pharmacy Randomization 
Log and will document the date of the request, the name of the research personnel making the 
request, and the pharmacist’s signature. The research coordinator will report the emergent 
event on the Adverse Event CRF and the unmasking event on the Unmasking Report CRF and 
then signed by the investigator.   
All SAEs will also  be reported to AstraZeneca  within 24 hours , whether or not 
considered causally related to the investigatio nal product.  All SAEs will be documented.  The 
investigator is responsible for informing the IRB and/or the regulatory authority (FDA) of the 
SAE .  
6.4.4 Laboratory safety assessment  
 We will obtain the following safety  laboratory samples at the screening visit  before 
initiating of study medications and  at the end of each study drug  period:  comprehensive 
metabolic panel including fasting blood glucose  and CBC and platelets , urine albumin 
assessment and lipid profile.   
At the screening visit  (Visit 1) , we will a lso obtain thyroid  function test  (TSH) , urine 
pregnancy test and u rine analysis . 
For blood volume see Section 7.1. 
6.4.5 Physical examination  
 Complete physical examination will be performed by either p rinciple investigator or 
co-investigators. It will include  general appearance, vital signs, and comprehensive  systematic 
examinations including head and neck, cardiovascular exam, respiratory exam, 
gastroenterology exam, extremit ies, skin and neurology exam.  
6.4.6 ECG  
 We will record baselin e ECG while lying  in all participants by using standard  ECG 
monitoring device (Mortara Instrument, ELI 250).   
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
35(91) 6.4.6.1  Resting 12 -lead ECG  
  12-lead ECG including I , II, III, aVR, aVL, a VF, V1 - V6 will be recorded with 
standardiz ed devices and stored at  the resea rch facility . Morphology of waves  at various leads , 
RR interval, corrected QT interval, and ST depression  will be e valuated  by the study 
investigator s and recorded in the flow chart.  
6.4.6.2  Real time display (telemetry) : NA  
6.4.7 Vital signs   
 It will include  temperatu re, resting blood pressure, heart rate, weight in kg, height in 
cm, and calculated BMI.  
6.4.7.1  Pulse and blood pressure  
 Systolic and diastolic blood pressure as well as pulse rate (electronically or by 
palpation,  count for 1 minute) will be measured after a pprox imately 5  minutes of rest in the 
seated position. The blood pressure measurement should be performed three times at each 
time point and the mean value of these measurements will be entered in the CRF.  
6.4.7.2  Body temperature  
 All participants’ body temperature wi ll be recorded in C RF by using standard Welch 
Allyn Sure Temp Plus device.  
6.4.8 Other safety assessments  
 Home Blood Glucose Monitoring  
All patients will be provided with a glucometer for home blood glucose monitoring 
and supplies for use at home during 12 -week intervention periods and wash -out period. 
Instruction on the proper use of the glucometer will  be provided by the study staff. The patient 
will be asked to moni tor glucose 2 times daily, in the morning and before dinner and to record 
the results of the g lucose log book that will be included in the patient source document file.  
6.5 Patient reported outcomes (PRO) :  
 NA 
6.5.1.1  <<Name of PRO method or questionnaire>>   
 NA 
6.6 Pharmacokinetics  
 Bloo d samples for pharmacokinetic evaluation will not be collected before and a fter 
initiating of study medications in this crossover study. Primary outcomes include changes in 
measures of cardiovascular autonomic neuropathy among patients taking glimepiride or 
dapagliflozin.   
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
36(91)  The followings are the pharmacokinetic activities of FD A approved dapagliflozin and 
glimepiride.  
 
Dapagliflozin  
Absorption  
Dapagliflozin is rapidly and well absorbed after oral administration and can be 
administered  with or without food. Maximum dapagliflozin plasma co ncentrations (Cmax) are 
usually attained within 2 hours after administration in the fasted  state. The Cmax and AUC 
values increase proportionally to the increment in dapagliflozin dose. The absolute o ral 
bioavailability of dapagliflozin following the administrati on of a 10 mg dose is 78%. Food has 
relatively modest effects on the pharmacokinetics of dap agliflozin in healthy subjects. 
Administration with a high -fat meal decreases dapagliflozin Cmax by u p to 50% and 
prolonged Tmax by approximately 1 hour, but does not alter AUC as compared with the 
fasted state. These changes are not considered to be clinically meaningful.  
Distribution  
Dapagliflozin is approximately 91% protein bound. Protein binding is not altered in 
various  disease states ( e.g., renal or hepatic impairment).  
Metabolism  
Dapagliflozi n is a C -linked glucoside, meaning the aglycone component is attached to 
glucose  by a carbon -carbon bond, thereby conferring stability agains t glucosidase enzymes. 
The mean plasma terminal half -life (t1/2) for dapagliflozin is 12.9 hours following a single  
oral dose of dapagliflozin 10 mg to healthy subjects. Dapagliflozin is extensively metabo lized, 
primarily to yield dapagliflozin 3 -O-glucuronide, which is an inactive metabolit e. 
Dapagliflozin 3 -Oglucuronide accounted for 61% of a 50 mg [14C] -dapagliflo zin dose and is 
the predominant drug-related component in human plasma, accounting for 42 % (based on 
AUC [0 -12 hour]) of total plasma radioactivity, similar to the 39% contribution b y parent 
drug. Based on AUC, no other metabolite accounts for >5% of the tot al plasma radioactivity. 
Dapag liflozin 3 -Oglucuronide or other metabolites do not contribute to th e glucose -lowering 
effects. The formation of dapagliflozin 3 -O-glucuronide is mediated by UGT1A9, an enzyme 
present in the liver and kidney, and CYP -mediated metabolism is a minor clearance pathway 
in humans.  
Elimination  
Dapagliflozin and related metabolites are primarily eliminated via urinary excretion, of 
which  less than 2% is unchanged dapagliflozin. After administrati on of 50 mg [14C] -
dapagliflozin dose, 9 6% is recovered; 75% in urine and 21% in feces. In feces, approximately 
15% of the dose is excreted as parent drug.  
 
Glimepiride  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
37(91) Absorption  
Studies with single oral doses of glimepiride in healthy subjects and with multiple oral 
doses in patients with type  2 diabetes showed peak drug concentrations (Cmax) 2 to 3 hours 
post-dose. When glimepiride was given with meals, the mean Cmax and AUC (area under the 
curve) were decreased by 8% and 9%, respectively.  Glimepiride does not accumulate in serum 
following mul tiple dosing. The pharmacokinetics of glimepiride does not differ between 
healthy subjects and patients with type 2 diabetes. Clearance of glimepiride after oral 
administration does not change over the 1 mg to 8 mg dose range, indi cating linear 
pharmacokin etics. In healthy subjects, the intra - and inter -individual variabilities of 
glimepiride pharmacokinetic parameters were 15 -23% and 24 -29%, respectively.  
Distribution  
After intravenous dosing in healthy subjects, the volume of distribution (Vd) was  
8.8 L ( 113 mL/kg), and the total body clearance (CL) was 47.8 mL/min. Protein binding was 
greater than 99.5%.  
Metabolism  
Glimepiride is completely metabolized by oxidative biotransformation after either an 
intravenous or oral dose. The major metabolites are the c yclohexyl hydroxy methyl derivative 
(M1) and the carboxyl derivative (M2). Cytochrome P450 2C9 is involved in the 
biotransformation of glimepiride to M1. M1 is further metabolized to M2 by one or several 
cytosolic enzymes. M2 is inactive. In animals, M1 po ssesses about one -third of the 
pharmacological activity of glimepiride, but it is unclear whether M1 results in clinically 
meaningful effects on blood glucose in humans.  
Excretion  
When 14C -glimepiride was given orally to 3 healthy male subjects, approximat ely 
60% of the total radioactivity was recovered in the urine in 7 days. M1 and M2 accounted for 
80-90% of the radioactivity recovered in the urine. The ratio of M1 to M2 in the urine was 
approximately 3:2 in two subjects and 4:1 in one subject. Approximat ely 40% of the total 
radioactivity was recovered in feces. M1 and M2 accounted for about 70% (ratio of M1 to M2 
was 1:3) of the radioactivity recovered in feces. No parent drug was recovered from urine or 
feces. After intravenous dosing in patients, no sig nificant biliary excretion of glimepiride or its 
M1 metabolite was observed.  
 
6.6.1 Collection of samples    
 NA 
6.6.2 Determination of drug concentration : NA  
 Determination of drug concentration will not be investigated in this study.  
6.7 Pharmacodynamics  
 No pharmacodyn amics  parameters will be determined in this study.  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
38(91) 6.7.1 Collection of pharmacodynamics  markers :  
 NA 
6.8 Pharmacogenetics : NA  
 No pharmacogenetic  samples will be investigated in this study.  
6.8.1 Collection of pharmacogenetic samples : NA  
 
6.9 Health economics  
  This study is  a pilot crossover clinical trial comparing 12 weeks of glycemic 
intervention on measures of cardiovascular autonomic neuropathy in patients with type 2 
diabetes. The duration of the  study  is quite short . Therefore,  it is likely that  this study won’t be 
able to o ffer health economics parameters. However,  we may consider performing analysis of 
glucose control and risk of hypoglycemic in study patients.  
7. BIOLOGICAL SAMPLING PROCEDURES  
7.1 Volume of blood  
   The study staff will collect 4 tubes of blood samples in  screening visit  (visit 1), visit 5, 
and visit  9. We will also collect 1 tube of blood sample at visit 6. Each tube contains  6ml 
blood sample (each  tube 6 ml = 1 teaspoon ). A total of 78 ml (13 teaspoons) of blood per 
subject will be taken for the entire s tudy.  
7.2 Handling, storage and destruction of biological samples  
  We will obtain all safety laboratory sam ples after overnight  fasting at screening visit 
before initiating of study medications and at the end of each intervention period. Sample 
will be marke d using subject unique study ID number. Study coordinator will keep separate 
list that links personal identity to ID number until all data have been analyzed and verified. 
All safety laboratory including HbA1c, liver transaminases (AST, ALT), alkaline 
phos phatase, serum creatinine, hematocrit, hemoglobin, red blood cell count, white blood 
cell count, platelet count, electrolytes (sodium, potassium, chloride, bicarbonate, Chloride, 
Calcium, bilirubin, Urea, total protein, albumin, FBG ), lipid panel (Total ch olesterol, 
Triglycerides, HD L, LDL) will be processed immediately after collection. Then we will 
dispose those blood samples  to the container labeled as Biohazard through Hazardous 
Materials Management (HMM) for the collection of liquid biohazardous waste .  
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
39(91) 7.2.1 Pharmacokinetic and/or pharmacodynamics  samples  
  No pharmaco kinetic and pharmacodynamics  samples will be collected during the 
study  
7.2.2 Pharmacogenetic samples :   
No pharmacogenetics sam ples will be collected during the study  
7.3 Labeling  and shipment of bioha zard samples  
 NA 
7.4 Chain of custody of biological samples  
 NA 
7.5 Withdrawal of informed consent for donated biological samples  
A subject may withdraw from the trial at any time at their own request, or they may be 
withdrawn at any time at the discretion of the investigator or sponsor for safety, behavioral, 
or administrative reasons.  If the subject withdraws consent, no further evaluations should 
be performed and no attempts should be made to collect additional data . We will not 
process stored biological sample s of such particular  subject. It will be disposed safely 
through HMM.  
8. ETHICAL AND REGULATO RY REQUIREMENTS  
8.1 Ethical conduct of the study  
  The trial will be performed in accordance with the protocol, International Conference 
on Harmonization Good Clinical P ractice guidelines, and applicable local regulatory 
requirements and laws.  
8.2 Ethics and regulatory review  
  Institutional Review Board (IRB)  
It is the responsibility of the investigator to obtain prospective approval of the trial 
protocol, protocol amendmen ts, informed consent forms, and other relevant documents, e.g., 
advertisements, if applicable, from the IRB.  All correspondence with the IRB should be 
retained in the Investigator File.  
8.3 Informed consent  
 The informed consent form must be agreed to by the Protocol Committee and the IRB 
and mu st be in compliance with ICH Good Clinical Practice Guidelines , local regulatory 
requirements, and legal requirements.  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
40(91) The investigator must ensure that each trial subject, or her legally acceptable 
representative, is f ully informed about the nature and objectives of the trial and possible risks 
associated with participation.  The investigator will obtain written informed consent from each 
subject or the subject's legally acceptable representative before any study -specif ic activity is 
performed.  The informed consent form used in this trial, and any changes made during the 
course of the trial, must be prospectively approved by the IRB before use.  The investigator 
will retain a copy of each subject's signed consent form.  
Study records with the study participant’s information for internal use at the clinical 
sites will be secured at the study site during the study. At the end of the study, all records will 
continue to be kept in a secure location. There are no plans to dest roy the records.  
Study participant data, which is for reporting purposes, will be stored at the 
Coordinating Center. Data will identify participants by the unique study identification number. 
The study data entry and study management systems used by clini cal sites and by 
Coordinating Center research staff will be a secured, password protected computer.  
8.4 Changes to the protocol and informed consent form  
 NA 
8.5 Audits and inspections  
  Audits and inspections  may be pursued by the Michigan Institute of Clinical R esearch 
as part of implementing quality assurance of the study trial and the time interval of audits will 
be scheduled  based on discretion of the se parties .  
9. STUDY MANAGEMENT  
 The principle investigator  and co -investigators  will be resp onsible for oversigh t of all 
aspects of the study. The study wil l be conducted according to ICH Good Clinical Practice 
Guidelines and i n accordance with University of Michigan Health System ( UMHS ) policies.  
9.1 Training of study site personnel  
 A delegation log of research pe rsonnel will be generated. The study staff will be 
trained for the following study procedures and certified by principle investigator:  
 Heart rate variability (HRV) studies,  
 Cardiova scular reflex tests (CARTs)  
 Freestyle Libre Pro CGM  
The efficiency  of trainin g of study staff wil l be periodically assessed by pr inciple 
investigator. All study staff should be certified for Program for Education and Evaluation in 
Responsible Research and Scholarship (PEERRS)  as part of regulation by Michigan Institutes 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
41(91) for clini cal and Heath research (MICHR). These courses  provide training required per 
university, state, and federal regulations regarding responsible conduct of research (RCR). 
The study staff will be also trained to report all un -anticipated events, deviations, and AEs to 
IRBMED.  
9.2  Monitoring of the study  
9.2.1 Source data  
 Protocol for Case Report Form (CRF) will be developed and serve d as the source 
document. Source documents provide evidence for the existence of the patient and 
substantiate the integrity of the data col lected.  We will record all medical history, physical 
examination, safety laboratory assessment  and all procedures involved during  the study in 
CRF. It is the investigator's responsibility to ensure completion and to review and approve all 
CRFs.  Additional  source data will be in patients’ medical record in electronic med ical record 
aka Michart. Michart  will also be used as source document. Outside medical record may also 
be requested for source document.  
9.3 Study timetable and end of study  
 Projected study ti melines are as the following:  
Research Agreement executed: Oct 30, 2016  
Projected IRB/IEC approval: Nov 30 , 2016  
First Subject In: Dec 30, 2016  
50% Enrollment: Sep 30, 2017  
Last Subject In (100% enrollment): Jun 30, 2018  
Last Subject Last Visit (Treatment  end): Dec 30, 2018  
Publication: Mar 30, 2019  
10. DATA MANAGEMENT  
 Case Report Forms / Electronic Data Record  
As used in this protocol, the term case report form (CRF) should be understood to refer 
to either a paper form or an electronic data record or both, depending on the data collection 
method used in this trial.  
A CRF is required and should be completed for each included subject.  It is the 
investigator's responsibility to ensure completion and to review and approve all CRFs.  CRFs 
must be signed by the i nvestigator or by an authorized staff member.  These signatures serve 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
42(91) to attest that the information contained on the CRFs is true.  At all times, the investigator has 
final personal responsibility for the accuracy and authenticity of all clinical and labo ratory 
data entered on the CRFs.  Subject source documents are the physician's subject records 
maintained at the trial site.  In most cases, the source documents will be the hospital's or the 
physician's chart.  In cases where the source documents are the hospital or the physician's 
chart, the information collected on the CRFs must match those charts.  
In some cases, the CRF may also serve as the source doc ument.  In these cases, the 
investigator must prospectively document which items will be recorded in t he source 
documents and for which items the CRF will stand as the source document.  
11. EVALUATION AND CALCU LATION OF 
VARIABLES  
      NA 
11.1 Calculation or derivation of efficacy variable(s)  
 NA 
11.2 Calculation or derivation of safety variable(s)  
 NA 
11.2.1  Other significant adverse events ( OAE)  
 NA 
11.3 Calculation or derivation of patient reported outcome variables  
 NA 
11.4 Calculation or derivation of pharmacokinetic variables  
 NA 
11.5 Calculation or derivation of pharmacodynamic variable(s)  
 NA 
11.5.1  Calculation or derivation of the relationsh ip between pharmacokinetic and 
pharmacodynamic variables  
 NA 
11.5.2  Population analysis of pharmacokinetic/pharmacodynamic variables  
 NA 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
43(91) 11.6 Calculation or derivation of pharmacogenetic variables  
 NA 
11.7 Calculation or derivation of health economic variables  
 NA 
12. STATIS TICAL METHODS AND SA MPLE SIZE 
DETERMINATION  
12.1 Description of analysis sets  
12.1.1  Efficacy analysis set  
 The primary efficacy analysis set will be based on a pharmacodynamic set such that 
subjects must have non -missing observations of study endpoints in both period s. A secondary  
analysis will be performed on the intent -to-treat (ITT) s et which includes  all patients who 
receive at least 1 dose of treatment . 
12.1.2  Safety analysis set  
 All patients will be evaluable for toxicity from the time of their first treatment.  All 
safety laboratory measurements  (see section 6.4.5 ) and  any reported or observed AEs (see 
section 6.4.3) will be documented in source document.  
12.2 Methods of statistical analyses  
 The primary objective of this trial is to compare the change in the LF : HF ratio from 
baseline to 12 weeks for patients on dapaglifozin versus glimepiride.  
The mean change in LF: HF ratio for each drug from baseline to 12 weeks will be 
reported with the corresponding 95% confidence interval. The mean difference between drugs 
of change s from baseline to 12 weeks and the corresponding 95% confidence interval will also 
be reported. The change from baseline to 12 weeks within each period (between drugs) will be 
compared within patients using a two -sided t -test (applying transformations whe re 
appropriate ; using the pharmacodynamics set of subjects) . This analysis will be repeated using 
the ITT set of subjects.   If there is chance within -subject or between -subject imbalance in 
baseline measures (such as glucose control, BMI and age), we will use the ANCOVA method 
including those unbalanced covariates to improve precision (Metcalfe, Statistics in Medicine, 
The analysis of cross -over trials with baseline measurements, 2010).  
A corresponding primary analysis to the t -test controlling for possible  sequence and 
period effects includes  a linear mixed effects model (also known as random effects model; 
applying transformations where appropriate) with outcome of the change in LF: HF ratio from 
baseline to 12 weeks . This model  assesses the difference bet ween drugs by accounting for  a 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
44(91) random effect for subject (nested within sequence) and fixed effects for treatment, sequence, 
and period.    
We will additionally explore differences between the drugs over time using all of the 
data measured at baseline, 4, 8  and 12 weeks with a linear mixed model . The outcome will be 
the change from baseline at 4, 8 and 12 weeks.  The model will include a  random term for 
subject nested within sequence and fixed effects for treatment, sequence, visit, period, and 
interaction te rms for visit by treatment.  The interaction terms for visit by treatment provide 
estimates of treatment effects at each visit.  An unstructured variance/covariance matrix will be 
used. 
 All secondary endpoints will be similarly compared where each endpoint for each 
drug will be measured at baseline and 12 weeks and the difference within each drug will be 
compared within patients using a two -sided t -test (applying transformations where 
appropriate). Similar to the analysis for the main outcome, linear mixed e ffect models  with an 
unstructured variance/covariance matrix  and outcomes of changes from baseline at 4, 8, and 
12 weeks  will assess  changes over time for  each outcome . The mixed effects models will 
include a random effect for patients nested within sequen ce and fixed effects for treatment, 
sequence, visit, period and the interaction between treatment and visit.  
Associations between the indices of glucose variability and changes in measures of 
HRV during each intervention will be analyzed using paired t -tests or Wilcoxon signed rank 
test (if normality assumption is violated). Effect sizes will be estimated with 95% confidence 
intervals of the associations between glucose variability and changes in measures of HRV 
within each intervention using linear regress ion (applying transformations when necessary). If 
period effects are found from our primary analysis, we will control for the period in which the 
drug was given within the model. The interaction between drug and glucose variability o n the 
changes in measur es of HRV  will be explored using a generalized estimating equations (using 
an unstructured working correlation matrix since we only have 2 observations per person). We 
will not control for multiple comparisons and expect results to be validated in a future  
independent cohort.  
12.2.1  Interim analyses  
 No interim analysis is planned . The study medications, dapagliflozin and glimepiride, 
are FDA approved drugs for treatment of type 2 diabetes. They are very effective in lowering 
glucose . There is no harm in continuin g treatment for the entire study period due to their 
safety  profile as mentioned above (see section 1.4 and 13).  
12.3 Determination of sample size  
 We assume there are no carryover effect and no interactions between patients, 
treatments, and time period.  For each patient in each period (on each drug), the LF : HF ratio 
will be measured at baseline and at 12 weeks. The primary outcome will be the difference 
between periods (drugs) in the differences from baseline to 12 weeks of the LF : HF ratio (i.e. 
[LF: HF sulfonylurea , week12  – LF: HF sulfonylurea, baseline ] – [LF: HF dapagliflozin , 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
45(91) week12  – LF: HF dapagliflozin,  baseline] ). Based on previous studies, we have found the LF : 
HF ratio to have a mean of 3.4 (SD=2.1) for those with T2D. Assuming a similar within 
person standard deviation  (2.1)  of the difference of the differences in the LF : HF ratio from 
baseline to 12 weeks, we have 80% power with 38 patients to find a difference between the 
two drugs in the differences in LF : HF ratios of 1.4 using a two -sided (paired) t-test at the 0.05 
significance level (sample size from applet available at 
http://hedwig.mgh.harvard.edu/sample_size/js/js_crossover_quant.html). Expecting 10% of 
the subjects to not complete the en tire study, we plan to enroll 45  patients.  
12.4 Data mo nitoring committee  
 A Data and Safety Monitoring Board (DSMB) will oversee this study.  This is the 
single center cross -over pilot study using on -label study medications. Therefore,  we feel that 
composing DSMB with an endocrinologist and a biostatistician  would be appropriate to 
monitor the study. Members of the DSMB are independent of the study investigators and 
study biostatistician.   The DSMB will meet every six months .  During the DMSB’s meetings, 
the team will discuss matters related to: enrollment r ate relative to expectations; 
characteristics of participants; safety of study participants (SAE and AE reporting); adherence 
to protocol (protocol deviations); completeness, validity and integrity of study data; and 
retention of study participants.  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
46(91) 13. IMPOR TANT MEDICAL PROCEDU RES TO BE 
FOLLOWED BY THE INVE STIGATOR  
  Given the mechanistic  nature of the study drug, dapagliflozin, the common side 
effects are urinary tract infection (UTI) and genital mycotic infection. Those patients who 
developed infections wil l be managed according to standard care and guidelines. Baseline 
urinary analysis (UA) will be collected before starting any study medications. In any case of 
suspect UTI, UA will be collected. If positive urine analysis, then we will proceed with urine 
culture and treat the patient according ly to bacterial growth in the urine culture. If negative 
UA, we will not proceed with midstream urine culture.  
 If the patient has abnormal ECG, the study investigator will ask the prior documented 
ECG report from pati ent’s primary care provider or endocrinologist and repeat the ECG. If the 
patient is symptomatic, then patient will be sent to emergency department for further urgent 
evaluation of coronary artery disease. The study medication will b e discontinued. If 
asym ptomatic , then the investigators will ask the prior ECG report and repeat ECG in the 
same visit. If similar findings compared to the old one, then he will be monitored 
conservatively. If significant changes from prior ECG, then he will be referred to the 
cardiologist for further evaluation upon the investigator’s discretion.  
13.1 Overdose  
Orally administrated dapagliflozin has been shown to be safe and well tolerated in 
healthy subject s at single doses up to 500 mg [ 50 times the  maximum  recommended human 
dose (MRHD) ]. These subjects had detectable glucose in the urine for a dose -related period of 
time (at least 5 days for the 500 mg dose) with no reports of dehydration, hypotension, or 
electrolyte imbalance, and with no clinically meaningful effect on QTc inter val. In clinical 
studies where once -daily doses of up to 100 mg (10 times the MRHD) of dapagliflozin were 
administered for 2 weeks in healthy subjects and type 2 diabetes patients, the incidence of 
hypoglycemia for subjects administered dapagliflozin was s lightly higher than placebo and 
was not dose related. Rates of adverse events including dehydration or hypotension for 
patients treated with dapagliflozin were similar to placebo, and there were no clinically 
meaningful dose -related changes in laboratory p arameters including serum electrolytes and 
biomarkers of renal function. In the event of an overdose, appropriate supportive treatment 
should be initiated as dictated by the patient’s clinical status.  
If an overdose on an AstraZeneca study drug occurs in t he course of the study, then 
sponsor  or other site personnel inform appropriate AstraZeneca representatives within  one 
day, i.e., immediately but no later than the end of the next business day  of when he or she 
becomes aware of it.  
 An over dosage  of glime piride , as with other sulfonylureas, can produce severe 
hypoglycemia.  Mild episodes of hypoglycemia can be treated with oral glucose. Severe 
hypoglycemic reactions constitute medical emergencies requiring immediate treatment. 
Severe hypoglycemia with coma,  seizure, or neurological impairment can be treated with 
Clinical Study Protocol  
Drug Substance Dapa gliflozin  
 
47(91) glucagon or intravenous glucose. Continued observation and additional carbohydrate intake 
may be necessary because hypoglycemia may recur after apparent clinical recovery . 
 The designated AstraZeneca  representa tive works with the sponsor  to ensure that all 
relevant information is provided to the AstraZeneca Patient Safety data entry site.  
13.2 Pregnancy  
 All female reproductive aged particip ants will be asked to use a definitive form of 
contraception befor e enrolling in the study. However,  pregnancy might occur in the study 
period. Once a female subject has been enrolled into the clinical trial, after having taken study 
medication, the investigator must report immediately any drug exposure during pregnancy and 
stop the study medication.  The outcome of the pregnancy associated with the drug exposure 
during pregnancy must be followed up.  All outcomes of pregnancy should be reported to 
AstraZeneca.  
13.2.1  Maternal  exposure  
Dapagliflozin is pregnancy category drug C. Based on the results of reproductive and 
developmental toxicity studies in animals, dapagliflozin doses  > 137 MRHD may affect renal 
development and skeletal malformation and maturation.  
Glimepiride is pregnancy category drug C. There are no adequate and w ell-controlled 
studies in pregnant women. In animal studies there was no increase in congenital anomalies, 
but an increase in fetal deaths occurred in rats and rabbits at glimepiride doses 50 times (rats) 
and 0.1 times (rabbits) the maximum recommended hum an dose (based on body surface area).  
As so on as we learn that a female subject has been pregnant, we will stop the study 
medication immediately. We will report this to AstraZeneca and IRBMED immediately. 
Patient will be asked to follow with her Obstetrici an closely. We will also follow the 
pregnancy outcomes and report this to AstraZeneca.  
13.2.2  Paternal exposure  
 Dapagliflozin had no effects on mating, fertility, or early embryonic development in 
treated male or female rats at exposure multiples ≤1708 times and  998 times the maximum 
recommended human dose in males and females, respectively.  
There was no effect of glimepiride on male mouse fertility in animals exposed up to 
2500 mg/kg body weight (>1,700 times the maximum recommended human dose based on 
surface area). Glimepiride had no effect on the fertility of male and female rats administered 
up to 4000 mg/kg body weight (approximately 4,000 times the maximum recommended 
human dose based on surface area).   
Therefore,  male subjects may have chi ldren while on s tudy medications.   
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
48(91) 14. LIST OF REFERENCES  
1. Sloan, F.A., et al., THe growing burden of diabetes mellitus in the us elderly 
population.  Archives of Internal Medicine, 2008. 168(2): p. 192 -199. 
2. Bennett, W.L., et al., Comparative Effective ness and Safety of Medications for Type 2 
Diabetes: An Update Including New Drugs and 2 -Drug Combinations.  Annals of 
internal medicine, 2011. 154(9): p. 602 -613. 
3. Häring, H. -U., et al., Empagliflozin as Add -On to Metformin in Patients With Type 2 
Diabete s: A 24 -Week, Randomized, Double -Blind, Placebo -Controlled Trial.  Diabetes 
Care, 2014. 37(6): p. 1650 -1659.  
4. Henry, R.R., et al., Dapagliflozin, metformin XR, or both: initial pharmacotherapy for 
type 2 diabetes, a randomised controlled trial.  Internatio nal Journal of Clinical 
Practice, 2012. 66(5): p. 446 -456. 
5. Wilding, J.P.H., et al., A Study of Dapagliflozin in Patients With Type 2 Diabetes 
Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel 
insulin -independent treatmen t. Diabetes Care, 2009. 32(9): p. 1656 -1662.  
6. Bailey, C.J., et al., Effect of dapagliflozin in patients with type 2 diabetes who have 
inadequate glycaemic control with metformin: a randomised, double -blind, placebo -
controlled trial.  The Lancet. 375(9733) : p. 2223 -2233.  
7. Cefalu, W.T., et al., Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk 
Factors in High -Risk Patients With Type 2 Diabetes: A 24 -Week, Multicenter, 
Randomized, Double -Blind, Placebo -Controlled Study With a 28 -Week Extension.  
Diabetes Care, 2015. 38(7): p. 1218 -1227.  
8. Kovacs, C.S., et al., Empagliflozin improves glycaemic and weight control as add -on 
therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: 
a 24-week, randomized, placebo -controlle d trial.  Diabetes, Obesity and Metabolism, 
2014. 16(2): p. 147 -158. 
9. Heerspink, H.J.L., et al., Dapagliflozin a glucose -regulating drug with diuretic 
properties in subjects with type 2 diabetes.  Diabetes, Obesity & Metabolism, 2013. 
15(9): p. 853 -862. 
10. Inzucchi, S.E., et al., SGLT -2 inhibitors and cardiovascular risk: Proposed pathways 
and review of ongoing outcome trials.  Diabetes & Vascular Disease Research, 2015. 
12(2): p. 90 -100. 
11. Cherney, D.Z.I., et al., The effect of empagliflozin on arterial stiffness and heart rate 
variability in subjects with uncomplicated type 1 diabetes mellitus.  Cardiovasc 
Diabetol, 2014. 13: p. 28.  
12. Zinman, B., et al., Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 
Diabetes.  New England Journal of Med icine. 0(0): p. null.  
13. Group, U.K.P.D.S., Intensive blood -glucose control with sulphonylureas or insulin 
compared with conventional treatment and risk of complications in patients with type 
2 diabetes (UKPDS 33).  The Lancet, 1998. 352(9131): p. 837 -853. 
14. Ohkubo, Y., et al., Intensive insulin therapy prevents the progression of diabetic 
microvascular complications in Japanese patients with non -insulin -dependent diabetes 
mellitus: a randomized prospective 6 -year study.  Diabetes Research and Clinical 
Practice, 1995. 28(2): p. 103 -117. 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
49(91) 15. Group, U.K.P.D.S., Effect of intensive blood -glucose control with metformin on 
complications in overweight patients with type 2 diabetes (UKPDS 34).  The Lancet, 
1998. 352(9131): p. 854 -865. 
16. Holman , R.R., et al., 10-Year Follow -up of Intensive Glucose Control in Type 2 
Diabetes.  New England Journal of Medicine, 2008. 359(15): p. 1577 -1589.  
17. The Action to Control Cardiovascular Risk in Diabetes Study, G., Effects of Intensive 
Glucose Lowering in Type 2 Diabetes.  The New England journal of medicine, 2008. 
358(24): p. 2545 -2559.  
18. Duckworth , W., et al., Glucose Control and Vascular Complications in Veterans with 
Type 2 Diabetes.  New England Journal of Medicine, 2009. 360(2): p. 129 -139. 
19. Group, T.A.C., Intensive Blood Glucose Control and Vascular Outcomes in Patients 
with Type 2 Diabetes.  New England Journal of Medicine, 2008. 358(24): p. 2560 -
2572.  
20. Erdmann, E., et al., PROactive 07: pioglitazone in the treatment of type 2 diabetes: 
results of the PROactive st udy. Vascular Health and Risk Management, 2007. 3(4): p. 
355-370. 
21. Kahn , S.E., et al., Glycemic Durability of Rosiglitazone, Metformin, or Glyburide 
Monotherapy.  New England Journal of Medicine, 2006. 355(23): p. 2427 -2443.  
22. Home, P.D., et al., Rosiglitazone evaluated for cardiovascular outcomes in oral agent 
combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open -
label trial.  The Lancet. 373(9681): p. 2125 -2135.  
23. Ratner, R., et al., Cardiovascular safety of exenatide BID : an integrated analysis from 
controlled clinical trials in participants with type 2 diabetes.  Cardiovascular 
Diabetology, 2011. 10: p. 22 -22. 
24. Marso, S.P., et al., Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.  New 
England Journal of Medic ine. 0(0): p. null.  
25. Nauck, M.A., et al., Dapagliflozin Versus Glipizide as Add -on Therapy in Patients 
With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A 
randomized, 52 -week, double -blind, active -controlled noninferiority trial.  Diabetes 
Care, 2011. 34(9): p. 2015 -2022.  
26. Jørgensen, C.H., et al., Glyburide increases risk in patients with diabetes mellitus after 
emergent percutaneous intervention for myocardial infarction — A nationwide study.  
International Journal of Cardiology , 2011. 152(3): p. 327 -331. 
27. Pantalone, K.M., et al., The Risk of Overall Mortality in Patients With Type 2 Diabetes 
Receiving Glipizide, Glyburide, or Glimepiride Monotherapy: A retrospective 
analysis.  Diabetes Care, 2010. 33(6): p. 1224 -1229.  
28. Crye r, P., Hypoglycemia: Still the Limiting Factor in the Glycemic Management of 
Diabetes.  Endocrine Practice, 2008. 14(6): p. 750 -756. 
29. Cryer, P.E., S.N. Davis, and H. Shamoon, Hypoglycemia in Diabetes.  Diabetes Care, 
2003. 26(6): p. 1902 -1912.  
30. Limberg , J., et al., Autonomic control during acute hypoglycemia in type 1 diabetes 
mellitus.  Clinical Autonomic Research, 2014. 24(6): p. 275 -283. 
31. Robinson, R.T.C.E., et al., Mechanisms of Abnormal Cardiac Repolarization During 
Insulin -Induced Hypoglycemia.  Diabetes, 2003. 52(6): p. 1469 -1474.  
32. Maalouf, R. and S. Bailey, A review on B -type natriuretic peptide monitoring: assays 
and biosensors.  Heart Failure Reviews, 2016: p. 1 -12. 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
50(91) 33. Maisel, A., B-Type Natriuretic Peptide Levels: Diagnostic and Prognostic  in 
Congestive Heart Failure: What’s Next?  Circulation, 2002. 105(20): p. 2328 -2331.  
34. Professional Practice Committee.  Diabetes Care, 2016. 39(Supplement 1): p. S3 -S3. 
35. Jaiswal, M., et al., Association Between Impaired Cardiovascular Autonomic Functi on 
and Hypoglycemia in Patients With Type 1 Diabetes.  Diabetes Care, 2014. 37(9): p. 
2616 -2621.  
36. Pop-Busui, R., What Do We Know and We Do Not Know About Cardiovascular 
Autonomic Neuropathy in Diabetes.  Journal of Cardiovascular Translational Research, 
2012. 5(4): p. 463 -478. 
37. Vinik, A.I. and D. Ziegler, Diabetic Cardiovascular Autonomic Neuropathy.  
Circulation, 2007. 115(3): p. 387 -397. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
51(91) Documentation of the Informed Consent Process for Onsite Subject File  
 
Protocol No.: HUM00121107          
Study Title/PI:  Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients 
with Type 2 Diabetes (T2D)  
Rodica Pop -Busui, Ph.D, M.D.  
Subject ID:             
Consent Obtained by:            
Date of Consent:           
  
15. CHECK ALL THAT APP LY 
 The subject meets all eligibility requirements.  
 Discussed, explained and reviewed the consent form with subject.  
 Verbal consent was obtained (per IRB approved consent process)  
 Surrogate consent was obtained (per  IRB approved consent process)  
 All of the subject’s questions were answered/concerns addressed.  (document 
multiple subject contacts below)  
 Subject did not have any questions/concerns  
 Subject was given time to review  the consent form and to discuss participation in 
this study with family members/others.  
 The subject has agreed to participate in the study and signed/dated a valid consent 
form prior to the start of any study procedures . 
 The consent process was witnessed by a third party (if applicable).   
Witnessed by:  
 A copy of the signed and dated consent form was given to the subject.  
 A copy of the signed and dated consent form was placed in th e medical record.  
 A copy of the signed and dated consent form was placed in the research record.  
Signature/I nitials:  Date:  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
52(91)  
MEDICAL HISTORY WORKSHEET  
DATE  _____________  
SUBJECT ID ____________________   STAFF INITIALS  _______________  
Record all past and/or concomitant medical conditions or surgeries. Record only one 
condition or surgery per line using the codes provided in the table. When recording a 
condition and surgery related to that condition use one line for the condition and one  line for 
the surgery . 
 
01 Head, Eye, Ear, Nose, Throat  
02 Respiratory  
03 Cardiovascular  
04 Gastrointestinal  
05 Genitourinary  06 Musculoskeletal  
07 Neurological  
08 Endocrine/Metabolic  
09 Blood/Lymphatic  
10 Dermatologic  11 Psychiatric  
12 Allergy  
91 Other  
 
 
Code   
Condition/Disease  
(one item per line)  Start Date  
dd/mmm/yyyy  Current /  
Resolved  
    Current  
 Resolved  
    Current  
 Resolved  
    Current  
 Resolved  
    Current  
 Resolved  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
53(91)     Current  
 Resolved  
    Current  
 Resolved  
    Current  
 Resolved  
    Current  
 Resolved  
    Current  
 Resolved  
    Current  
 Resolved  
    Current  
 Resolved  
 
 
 
 
 
 
 
 
 
 
 
PHYSICAL EXAMINATIO N WORKSHEET  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
54(91) DATE  __________  
 
SUBJECT ID ___________________   STAFF INITIALS  ___________  
 
Please complete checklist and describe any abnormalities.  
    Normal   Abnormal   Not done  
Eyes  (including fundoscopy)     ⎕      ⎕          ⎕       Retinopathy, macular degeneration  
 Other             __________________________  
Cardiovascular      ⎕      ⎕          ⎕       Arrhythmia, murmur  
 Other              ___________________________  
Extremities       ⎕          ⎕           ⎕        Amputation, tenderness, edema  
            Pulses:  1+  / 2+ /  3+ / 4+  
            Other                                                                      ___________________________  
Lymph Nodes                          ⎕             ⎕          ⎕       Swelling  
             Other                                                                     ____________________________  
Pulmonary                                ⎕           ⎕         ⎕      Decreased breath sounds  
           Other                                                                      ____________________________  
Skin                                           ⎕           ⎕          ⎕      Red or purple painful rash, 
scar,eczema,  
                                                                                           psoriasis, ulcer, excessive bruising  
          Other                                                                       ______________________________  
Gastrointestinal                      ⎕           ⎕          ⎕       Ascites, abdominal mass,  
                                                                                         Organomegaly, stoma  
          Other                                                                   ______________________________                       
Musculoskeletal                      ⎕           ⎕          ⎕       Joint pain  stiffness or swelling ,  
                                                                                          Muscle pain or weakness, difficulty   
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
55(91)                                                                                          walking or movin g                          
            Other                                                                   ______________________________                
Neurological                                ⎕             ⎕          ⎕     Abnormal reflexes (hypo/  
                                                                                            hyperreflexia ), decreased sensation                
                                                                                            cranial nerves (abnormal –  specify)  
         Other                                                                        ______________________________           
Reflexes                                     ⎕             ⎕         ⎕     ______________________________  
 
Other, specify:  
___________________________________________________________________________  
Is participant having any side effects from study meds?  Yes ⎕   No ⎕ 
If yes, specify:  
__________________________________________ _________________________________  
NOTE: If participant has side effects, complete AE worksheet and SAE worksheet (if 
necessary).  
If this is a screening Physical Exam, is participant eligible based in this exam?  
Yes  ⎕    No  ⎕   N/A ⎕ If no, explain:  
____ _______________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________ ________________________________________
___________________________________________________________________________  
 
 
Physician’s Name (printed): __________________________________________________  
 
Physician’s Signature:   ___________________________________ ___________________                                                                                                                                                    
           
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
56(91) Medical History Changes  
 
Subject ID: ____________________  Date: _____________ _____  
 
Visit: ____________  
Was there a change in your medical or surgical history?   Yes   No 
 If yes, describe: __________________________________________________  
____________________________________________________________________
_______________________ _____________________________________________
__________________________________________ __________________________  
 
Was there a change in your current m edications ?  Yes   No  
If yes, describe: ___________________________________________________  
__________ __________________________________________________________
____________________________________________________________________
____________________________________________________________________  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
57(91) Study  Title:   _DAPA -CAN  HUM00121107  
Subject ID :        
CONCOMITANT MEDICATIONS WORKSHEET    
Is the participant taken any concomitant medications at 
screening or during the prior 3 months      No         Yes, Complete below  
Medication  
(Record 
Generic or  
trade name)  Reason for use 
(Medical History 
diagnosis or other 
reason, e.g. 
Prophylaxis)  Dose 
and 
units  Frequency   
 
Route  Start Date  
(DD/MMM/YYYY)  Stop Date 
(DD//MMM
/YYY)  Or tick if 
ongoing at 
Screening 
Visit  
1.     
____/_____/_____   
____/_____/
_____           
2.     
____/_____/_____  ____/_____/
_____          
3.     
____/_____/_____  ____/_____/
_____          
4.  
    
____/_____/_____  ____/_____/
_____          
5.     
____/_____/_____  ____/_ ____/
_____          
6.     
____/_____/_____  ____/_____/
_____          
7.     
____/_____/_____  ____/_____/
_____          
8.     
____/_____/_____  ____/_____/
_____          
9.     
____/__ ___/_____  ____/_____/
_____   
10.     
____/_____/_____  ____/_____/
_____    
 
Staff Initials:    _____________  
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
58(91) DATE  _ _/_ _/_ _ _ _  
              mo           day                    yr   
SUBJECT ID   _ _ _    STAFF INITIALS      _ _ _   
Cardiovascular Autonomi c Neuropathy Testing Worksheet  
PREPAREDNESS FOR TESTING  
(If YES is answered to any of the questions below, patient is ineligible for CAN testing today.  
Reschedule the patient for testing another day and discard this form.)  
  No       Yes  
1.        Any food since in the past 12 hours?  (1)        (2)  
2.        Any liquids in the past 12 hours? (except water)  (1)        (2)  
3.        Any caffeine in the past 12 hours?  (1)        (2)  
4.        Any medication in the past 12 hours (excluding basal pump in sulin)?  (1)        (2)  
5.        Any over -the-counter drugs in the past 12 hours (aspirin, antihistamines, nasal 
spray, etc.) (1)        (2)  
6.        Any alcohol in the last 24 hours  (1)        (2)  
7.        Any tobacco in the past 12 hours?  (1)        (2) 
8.        Any vigorous exercise in the last 24 hours? (Any exercise not part of patient’s 
daily routine, i.e., routine jogging O.K., but marathon running is not.  NO exercise 
morning of test.)  (1)        (2)  
9.     Any emotional upset in the last 24  hours” (Depression, crying episodes, anxiety 
from personal trauma  (1)       (2)  
10.     Acute illness in last 48 hours? (cold, flu, measles, etc.).  (1)        (2)  
11.     Any hypoglycemic episodes since midnight?  (1)        (2)  
12 a) Fasting  blood sug ar value (finger stick method O.K.)  ___  ___ ___ 
mg/dl  
     b)  Below 50 or signs or symptoms of hypoglycemia?  (1)       (2)  
VITAL SIGNS   
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
59(91) 1. Height  
2. Weight  ___ ___ ___ . 
___(cm)   
___ ___ ___ . 
___(kg)  
3. BP 
4. Pulse  __ __ __ / __ 
__mmHg  
___ ___ ___ 
BPM  
List an y medications taken in the last 48 hours:  
 
 
 
 
 
 
 
 
 
 
 
Form completed by:_________________________________________________________  
 
 
 
 
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
60(91) DATE  _ _/_ _/_ _ _ _  
          mo               day                     yr   
SUBJECT ID   _ _ _    STAFF INITIALS      _ _ _   
 
Heart Rate Variability Test Report  
 
 
Technician’s Signature:_________________________  Date:______________  
Physician’s Signature:________________________  Date:______________  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
61(91) Adverse Event Monitoring  
 
Subject ID: ________________  
 
Date: ______________ ______  
 
Visit: ____  
 
Was there any new or worsening adverse events reported?  
Yes, new event(s)  
Yes, worsening event(s)  
Yes, both  
No 
Number of new or worsening adverse events: ________  
 Were any of the following events reported (check all that apply)?  
Urinary Tract Infection  
Genital Infection  
Hypotension  
Dehydration  
DKA 
Other  
If other, describe: 
__________________________________________________  
*If there was a new or worsening adverse event, fill out a corresponding AE 
form for each event.  
 
 
Completed By: __________________________________ Date: _______________  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
62(91) Adverse Event Form  
 
Subject ID: ___________________  
 
AE Number:  AE __ __  
 
Description  of AE: 
__________________________________ ___________________________  
______________________________ _______________________________  
 
Date this Report  Opened : _________________________  
 
Date this Report Closed: _________________________  
 
Most recently completed subject visit number (if event is reported in context of current 
visit, record today's visit number): _____________  
Date Adverse Event Started: ____________________  
(can be approximate or unsure)  
Date that the Study S taff Learned of the E vent:  ______________________  
 Date Adverse Event Abated: ________________________  
 (can be approximate or unsu re, leave blank until abated)  
  
   Check if ongoing at conclusion of study  
Indicate PI initial level of sever ity using the scale below:  
1 - Mild AE - No treatment needed  
2 - Moderate AE - Resolved with treatment  
3 - Severe AE - Inability to carry on normal  activities, required professional 
medical attention . 
4 - Life-threatening or disabling AE  
5 - Fatal AE  
Indicate the final PI level of sever ity using the scale below:  
1 - Mild AE - No treatment needed  
2 - Moderate AE - Resolved with treatment  
3 - Severe AE - Inability to carry on normal  activities, required 
professional medical attention . 
4 - Life-threatening or disabling AE  
5 - Fatal AE  
 v 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
63(91)  
Indicate the PI initially relation  to study particip ation.   
 
Definite  Probable  Possible  Unlikely  Unrelated  
 
 
Indicate the PI final relation  to study particip ation.  
 
Definite  Probable  Possible  Unlikely  Unrelated  
 
 
Was the event expected?         Yes  No 
 
What action was taken for the event reported (check all that apply)?  
No action taken        
Medication Prescribed  
Non-Drug Treat ment Prescribed (e.g., physical therapy)   
Study Medication Dose Reduced      
Study Medication Stopped  
Outpatient Medical Visit       
Urgent Care Visit    
Emergency Room Visit  
Hospitalization     
 
Other  
   
If other, d escribe:  __________________________________________  
 
Was medication stopped or reduced?           Yes          No 
 
Date dose was stopped or reduced: _______________________  
 
Did the adverse event abate after stopping/reducing study medic ation?  
 Yes  No 
 
If yes, has the study medication dose increased or restarted ?  
Yes No 
Date medication was increased or restarted: _____________________  v 
v 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
64(91)  
 
Was AE submitted to UM IRB?   Yes      No  Pending yearly submission  
 
Date of S ubmission : ___________________ ______  
 
Did this event meet the definition of a serious adverse event?  Yes      No  
*If this adverse event meet the definition of a serious adverse event, complete a 
serious adverse event form.   
 
Comments:  
 
 
 
 
 
 
 
 
 
 
 
 
Complete By: _____________________ __________________ Date: ____________  
 
Principal Investigator Signature: ____________________________ Date: _________  
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
65(91) Serious Adverse Event Form  
 
Subject ID: ____________________ __  
SAE Number: SAE __ __  
Description of Serious Adverse Event:  ____________ _________________________  
____________________________________________________________________  
Date this Report  Opened : ________________________  
Date this Report Closed: _________________________  
 
Most recently completed subject visit number (if event is  reported in context of current 
visit, record today's visit number): _____________  
Date Serious Adverse  Event Occurred/S tarted:  ____________________  
Date  that the Study Staff L earned of the E vent: _______________________  
Date Serious Adverse Event Abated:  ________________________  
 (can be approximate or unsure, leave blank until abated)   
   
   Check if ongoing at conclusion of study  
 
Is this a Death?  Yes  No 
Date of Death: ________________________  
Location of Death: ___________________________________ ____  
Probable Cause of Death: _________________________________  
Is this a Life -Threatening Event?   Yes  No 
Did the event result in inpatient hospitalization or prolongation of existing 
hospitalization?  
Yes  No 
If yes, number of days in hospital: ______ _____  
 v v 
v v 
v 
v v 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
66(91) Did the event result in persistent or significant incapacity or substantial disruption of 
the ability to conduct normal life functions?   
Yes  No 
Is the event a pregnancy resulting in a congenital anomaly or birth defect?   
Yes   No 
Was this a ser ious event in the judgment of the investigator that required medical or 
surgical intervention to prevent death, hospitalization of life -threatening outcomes?
  
Yes  No 
Was the event due to an overdose of study medication?  
Yes  No 
Indicate the PI initia lly relation  to study particip ation.   
 
Definite  Probable  Possible  Unlikely  Unrelated  
 
 
Indicate the PI final relation  to study particip ation.  
 
Definite  Probable  Possible  Unlikely  Unrelated  
 
Was the Event E xpected?       Yes  No 
Indicate PI initial level of sever ity using the scale below:  
1 - Mild AE - No treatment needed  
2 - Moderate AE - Resolved with treatment  
3 - Severe AE - Inability to carry on normal  activities, required professional 
medical attention . 
4 - Life-threatening or disabl ing AE  
5 - Fatal AE  
Indicate the final PI level of sever ity using the scale below:  
1 - Mild AE - No treatment needed  
2 - Moderate AE - Resolved with treatment  
3 - Severe AE - Inability to carry on normal  activities, required 
professional medical atte ntion . 
4 - Life-threatening or disabling AE  
5 - Fatal AE  v v 
v v 
v v 
v 
v v v 
v v 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
67(91)  
What action was taken for the event reported (check all that apply)?  
No action taken        
Medication Prescribed  
Non-Drug Treat ment Prescribed (e.g., physical therapy)   
Study Medication Dose R educed      
Study Medication Stopped  
Outpatient Medical Visit       
Urgent Care Visit    
Emergency Room Visit  
Hospitalization     
 
Other  
   
If other, describe:  __________________________________________  
 
Was medication stopped or reduced?           Yes           No 
 
Date dose was stopped or reduced: _______________________  
 
Did the event abate after stopping/reducing study medication?   Yes 
 No 
 
If yes, has the study medication dose increased or restarted ? 
Yes No 
Date medication was increased or res tarted: _____________________  
 
Was SAE submitted to UM IRB?     Yes      No  
 
Date of S ubmission : _________________________  
   
Comments:  
 
Completed by: __________________________________ ______ Date: __________  
Principal Investigator Signature: _________ _____________________ Date: _______  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
68(91) DATE  _ _/_ _/_ _ _ _  
        mo               day                     yr   
SUBJECT ID   _ _ _    STAFF INITIALS      _ _ _   
 
INSTRUCTIONS FOR HEART RATE VARIABILITY (HRV) TESTING  
CAN testing is done to evaluate the nerves  that help to regulate heart rate and blood pressure.   
Many factors can affect CAN test results, so for accurate testing, we ask that you read and 
follow these instructions carefully and completely.  As always, if you have any questions or 
concerns about these, please contact us so that we can discuss them.  
1.  FAST FOR 12 HOURS PRIOR TO TESTING and NO CAFFEINE 12 HOURS prior to 
testing.  You should have nothing to eat or drink except water for at least 12 hours before your 
appointment.  Water is fine, but  other beverages, even if they are de caffeinated, are to be 
avoided.  
2.  AVOID LOW BLOOD SUGAR.  Low blood sugar reactions can greatly affect CAN test 
results, so it is very important to avoid lows, even mild low blood sugar reactions in the 12 
hours befor e the test.  TAKE STEPS TO PREVENT LOW BLOOD SUGAR.  You may need 
to eat something before you go to bed, and / or reduce your evening or overnight insulin to 
prevent going low.  If you need help making insulin dose adjustments, please contact Dr. Pop -
Busui  AT 734 -647-9809 OR ASK OPERA TOR (734 -936-6267) TO PAGE HER.  
3.  DO NOT TAKE ANY MEDICATIONS for 12 hours prior to the test.  This includes 
prescription and over the counter medications.  Bring your medications (including your 
insulin) with you so that you  can take them as soon as the testing is done.  IF YOU HAVE 
QUESTIONS ABOUT THIS, OR CONCERNS ABOUT SPECIFIC MEDICATIONS THAT 
YOU TAKE THAT ARE ON A VERY SPECIFIC SCHEDULE PLEASE CONTACT DR. 
POP-BUSUI PRIOR TO Y OUR TEST.   
4.  NO ALCOHOL for 24 hours befor e the test.  Alcohol can interfere with the function of 
autonomic nerves, so any alcohol consumed in the 24 hours prior to your te st may lead to 
invalid results.  
5.  NO VIGOROUS EXERCISE for 24 hours prior to the test AND NO EXERCISE ON 
MORNING OF TEST.  E xercise that is part of your daily routine is fine in the 24 hours prior 
to testing (for example – routine jogging is okay, but running a marathon the day before 
testing is not – unless you run marathons on a daily basis).   
6.  SIGNIFICANT EMOTIONAL UPSET  within 24 hours of testing can also lead to invalid 
test results.  If something comes up the day before testing that is very upsetting, please call to 
discus s rescheduling the appointment.  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
69(91) 7.  ANY ACUTE ILLNESS IN THE 48 HOURS PRIOR TO TESTING (such as co lds, flu’s, 
dental work) may affect test results.  If you are sick or feeling unwell, please call and we can 
discuss whether or not we should reschedule this test.  
8.  NO SMOKING FOR AT LEAST 12 HOURS PRIOR TO TESTING.  If you do smoke, 
please do not have any cigarettes/cigars for at least the eight hours prior to testing.  
Finally, please bring your blood glucose monitor with you.  I will be asking you to check your 
blood sugar just before testing starts.  Thank you and please call or email if you have any 
questions about the CAN testing or these instructions.   
Dr. Rodica Pop -Busui: (734) 647 -9809; rpbusui@umich.edu   
Dr. Lynn Ang: (734) 232 -8058; angly@med.umich.edu  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
70(91) CASE  REPORT  FORM:   SCREENING  VISIT  (VISIT 1) 
SUBJECT  ID: ______________________  
 
VISIT  DATE:  __________________ ___ 
CONSENT  SIGNED:  
 
Eligibility  Checklist:  INCLUSION  CRITERIA  and EXCLUSION  CRITERIA  
 
Inclusion  Criteria  – All must  be 
checked  to be in study  EXCLUSION  CRITERIA – If any are checked,  cannot  be in 
the study  
Type  2  diabetes  History of recurrent  urinary tract infections  
At least 18 Years of age  Current participation or participation within the  
last three months in an experim ental drug study.  
BMI ≤45 kg/m2  Fungal  infection, especially genital infections  
Background metformin 
monotherapy  Severe  low blood  pressure  
Willing  and able to take an 
oral (by mouth)  medication  
once per day for 2 periods 
of 12 weeks . History of unexplained microscopi c or gross 
hematuria (blood in your urine)  (confirmed by 
follow -up) 
WOMEN  using  an 
appropriate  method  of 
contraception  during  the 
course  of the study  
(hormonal,  IUD, or 
diaphragm).  Allergy to an d/or have evidenced sensitivity (i.e. 
swelling, skin rashes ) to the study  medications (brand 
names: Farxiga and Amaryl) or other SGLT2  
 inhibitors (i.e. Jardiance, Invokana)  
 History of diabetic ketoacidosis  
 If you had a cardiovascular event (such as surgery, 
angioplasty, heart at tack, stroke, peripheral arte ry 
disease) in the last three months.  
 Severe kidney disease or rapidly progressing kidney 
disease  
Clinical Study Protocol  
Drug Substance Dapagliflozi n 
 
71(91)  Any clinical conditions that could interfere with the 
cardiovascular autonomic function and  heart rate 
variability testing (arrhythmias)  
 
 
 
  Severe l iver insufficiency and/or significant 
abnormal liver function  
 
 History of cancer other than basal cell carcinoma 
and/or treatment for cancer within the  last five years  
History of drug or alcohol  abuse  in prior 5 years.  
History of pancreas, kidney or l iver transplant  
Allergy to sulfa drugs  
Class III or IV congestive heart failure  
 
   
 
 
 
 
 
 
 
 
Completed by: _______________________________________________________________________   
 
 
 
 
 
Completed by: ___________________________________________________ ____________  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
72(91) Participant Information Survey  
HAS THE PATIENT PROVIDED SIGNED INFORMED CONSENT TO PARTICIPATE 
IN THIS RESEARCH STUDY?  Yes   No 
UMHS MRN : __________________________________  
Pronoun: _______  
First Name : __________________________________  
Last Name : __________________________________  
Date of Birth:  
Gender a t Birth :   Male   Female  
Ethnicity :   Hispanic or Latino       Not Hispanic or Latino         Unknown / Not 
Reported  
Race :              American Indian/Alaska    
Asian    
Native H awaiian or Other Pacific Islander  
Black or African American  
White  
More than One Race  
Unknown / Not Reported  
Date of Diabetes Diagnosis:         (MM-YYYY)  
Address, Street, City, State, ZIP : 
__________________________________________ ______   
Primary  Phone Number : ______________________________  
Secondary Phone Number: _______________________________  
Email Address : __________________________________  
Secondary Email Address : __________________________________  
Completed By: __________________________ _______________ Date: _________  v v v v v v v v v v 
 
v  
v 
 
v  
v  
v 
 
v 
 
v 
 
v 
 
v 
 
v 
 
v 
 
v 
v v v v v v 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
73(91)  
Visit 1 Overview and Screening Disposition  
 
 
SUBJECT ID: ____________________________  
 
Date: _________________________  
 
Weight (kgs): _____________________    Height (inches): _____________________  
 
Pulse (seated): _______ ___________    Blood Pressure (seated): __________________  
 
 
 
Assessments  
 
 Informed Consent     Performed by: ____________ _________  
 
Medical History and Physical Examination  Performed by: ________________ _____  
 
ECG       Performed by: _________________ ____  
 
Laboratory Measures     Performed by: ___ 
 
Urine Pregnancy Test Completed for Women and Result:  
 
Negative  Positive  Not Done  Not Applicable  
 
 
 
DISPOSITION: Eligible Not Eligible  
 
 
 
If eligible, schedule a baseline visit to occur within 30 days.  
 
BASELINE VISIT DATE: ___________________________  
 
 
Comments:  
 
 
 
 
 
 
 
Signature of Coordinator : _________________________________ Date: _______________  
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
74(91) Visit 2 Overvi ew 
 
 
SUBJECT ID: ____________________________  
 
Date: _________________________  
 
Weight (kgs): _____________________    Blood Pressure (seated): __________________  
 
Pulse (seated): __________________    Resting HR (supine from HRV): ________________  
 
Heigh t (inches): __________  
 
    
  
Assessments  
 
HRV Testing      Performed by:____  
 
CARTs Testing     Performed by: _____________________  
 
Assess Hypoglycemia    Performed by: _____________________  
 
Medication Dispensing    Performed by: __________________ ___ 
 
Adverse Events Monitoring    Performed by: _____________________  
 
Urine Pregnancy Test Completed for Women and Result:  
 
Negative  Positive  Not Done  Not Applicable     
 
 
VISIT 3 Scheduled for: ___________________________  
 
Comments:  
 
 
 
 
 
 
 
 
 
 
 
Signature of Coordinator: ___ ______________________________ Date: _______________  
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
75(91) Visit 3 Overview  
 
 
SUBJECT ID: _________________________Date: _________________________  
 
Weight (kgs): ________________ Blood Pressure (seated): __________________  
 
Pulse (seat ed): _________________Resting HR (supine 5 mins): _______________  
 
Height (inches): ___________________  
 
Assessments  
 
Assess Hypoglycemia   Performed by: ______________________  
 
Medication Compliance    Performed by: ______________________  
 
Adverse Even ts Monitoring  Performed by: ______________________  
 
 
Urine Pregnancy Test Completed for Women and Result:  
 
Negative  Positive  Not Done  Not Applicable  
 
 
VISIT 4 Scheduled for: ___________________________  
 
 
Comments:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature of Coordina tor:___________________________ Date: _______________  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
76(91) Visit 4 Overview  
 
 
SUBJECT ID: _________________________ Date: _________________________  
 
Weight (kgs): __________________ Blood Pressure (seated): __________________  
 
Pulse (seated): _____________ Res ting HR (supine 5 mins): __________________  
 
Height (inches): ___________________  
 
Assessments  
 
Assess Hypoglycemia   Performed by: ______________________  
 
Medication Compliance   Performed by: ______________________  
 
Adverse Events Monitoring  Performe d by: ______________________  
 
 
Urine Pregnancy Test Completed for Women and Result:  
 
Negative  Positive  Not Done  Not Applicable  
 
 
VISIT 5 Scheduled for: ___________________________  
 
 
Comments:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature of Coordinator:___________________ ________ Date: _______________  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
77(91) Visit 5 Overview  
 
 
SUBJECT ID: ____________________________ Date: _____________________  
 
Weight (kgs): ___________________ Blood Pressure (seated): _________________  
 
Pulse (seated): _______________ Resting HR (supine 5 mins ): ________________  
 
Height (inches): __________________  
 
Assessments  
 
Medical History and Physical Examination  Performed by: _____________  
 
Laboratory Measures     Performed by: _____________  
 
HRV         Performed by: _____________  
 
CARTs Testing       Performed by: _____________  
  
Medication Compliance     Performed by: _____________  
  
Adverse Events Monitoring    Performed by: _____________  
 
Assess Hypoglycemia      Performed by: _____________  
 
EKG        Performed by: _____________  
 
 
Urine Pregnan cy Test Completed for Women and Result:  
 
Negative  Positive  Not Done  Not Applicable  
 
 
VISIT 6 Scheduled for: ___________________________  
 
 
Comments:  
 
 
 
 
 
Signature of Coordinator: ___________________________ Date: _______________  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
78(91) Visit 6 Overview  
 
 
SUBJECT ID: ______________________ Date: _________________________  
 
Weight (kgs): _____________________    Height (inches): _____________________  
 
Pulse (seated): __________________    Blood Pressure (seated): _______________  
 
Resting HR (supine 5 mins): ___ ____________  
 
 
Assessments  
 
Medical History and Physical Examination Performed by: ________________  
 
ECG      Performed by: _______________________  
 
HRV      Performed by:  _______________________  
 
Laboratory Measures   Performed by:  ____________________ ___ 
 
CARTs Testing    Performed by:  _______________________  
 
Assess Hypoglycemia   Performed by:  _______________________  
 
Medication Dispensing   Performed by: ______________________  
 
Urine Pregnancy Test Completed for Women and Result:  
 
Negative  Positive Not Done  Not Applicable  
 
 
VISIT 7 Schedule for: ___________________________  
 
Comments:  
 
 
 
 
 
 
 
 
Signature of Coordinator: ___________________________ Date: _______________  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
79(91) Visit 7 Overview  
 
 
SUBJECT ID: ________________________Date: __________________ _______  
 
Weight (kgs): _____________________    Blood Pressure (seated): _____________  
 
Pulse (seated): __________________    Resting HR (supine 5 mins): ____________  
 
Height (inches): ___________________  
 
Assessments  
 
Assess Hypoglycemia   Performed by: ______________________  
 
Medication Compliance   Performed by: ______________________  
 
Adverse Events Monitoring  Performed by: ______________________  
 
 
Urine Pregnancy Test Completed for Women and Result:  
 
Negative  Positive  Not Done  Not Applicable  
 
 
VISIT 8 Scheduled for: ___________________________  
 
 
Comments:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature of Coordinator: ___________________________ Date: _______________  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
80(91) Visit 8 Overview  
 
 
SUBJECT ID: _______________________  Date: __________________  
 
Weight (kgs): ____ _________________    Blood Pressure (seated): _____________  
 
Pulse (seated): __________________    Resting HR (supine 5 mins): ___________  
 
Height (inches): ___________________  
 
Assessments  
 
Assess Hypoglycemia   Performed by: ______________________  
 
Medication Compliance   Performed by: ______________________  
 
Adverse Events Monitoring  Performed by: ______________________  
 
 
Urine Pregnancy Test Completed for Women and Result:  
 
Negative  Positive  Not Done  Not Applicable  
 
 
VISIT 9 Scheduled for: ____ _______________________  
 
 
Comments:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature of Coordinator: __________________________ Date: _______________  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
81(91) Visit 9 Overview  
 
 
SUBJECT ID: ________________________ Date: _________________________  
 
Weight (kgs): _____________________    B lood Pressure (seated):______________  
 
Pulse (seated): __________________    Resting HR (supine 5 mins): ____________  
 
Height (inches): __________________  
 
  
Assessments  
 
Medical History and Physical Examination Performed by: _________________  
 
Laborato ry Measures   Performed by: ______________________  
 
HRV       Performed by: ______________________  
 
CARTs Testing     Performed by: ______________________  
  
Medication Compliance   Performed by: ______________________  
  
Adverse Events Monitoring  Performe d by: ______________________  
 
Assess Hypoglycemia   Performed by: ______________________  
 
ECG       Performed by: ______________________  
 
 
Urine Pregnancy Test Completed for Women and Result:  
 
Negative  Positive  Not Done  Not Applicable  
 
Comments:  
 
 
 
 
 
 
 
 
Signature of Coordinator: ___________________________ Date: _______________  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
82(91) DATE  ___________   VISIT : _________                  
SUBJECT ID ______________   STAFF INITIALS  ____________  
 
 
EKG  Testing Cover Sheet  
 
 
Interpretation:  
 
 
 
 
Technician’s Signatur e: _________________________  Date: ______________  
 
Physician’s Signature: ________________________  Date: ______________  
 
 
 
 
 
 
 
 
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
83(91)  
ECG Report  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
84(91) DATE  _ _/_ _/_ _ _ _  
       mo               day                     yr   
SUBJECT ID   _ _ _    STAFF INITIALS      _ _ _   
 
Glucometer Download Data  
Technician’s Signature:_________________________  Date:______________  
 
Physician’s Signature:________________________  Date:______________  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
85(91) 
 
 
 
 
 
 
 
 
 
 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
86(91) Medication Dispensing  
 
 
Subject ID: _____________ ________  Date of Visit: _____________________      Visit: ________  
 
v  
Was medication picked up from IDS?   Yes   No  
 
Date picked up: ________________________  
 
Medication picked up by: __________________________________  
 
Prescription #: _________________ ________________  
 
Number of Tablets Dispensed: ______________________________  
 
Number of daily tablets prescribed by the treatment team at the conclusion of the visit today: ______  
 
Was the patient given  the study medication?   Yes  No  
 
Date patient rece ived study medication: _________________________  
 
Medication given to patient by: ________________________________  
 
Date patient started taking the study medication: _________________________  
 
 
Comments: _____________________________________________________ ____________________
_________________________________________________________ __________________________
____ _______________________________________________________________________________
______________________________________________________________________ _____________
___________________________________________________________________________________  
 
 
 
 
 
 
 
 
 
 
Form Completed by: ________________________________________  Date: ___________________  
 
 
 v v v v 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
87(91) Medication Compliance  
 
Subject ID: __________________  Visit  Date: ___________________   Visit: ________  
 
How often do you skip o r forget to take your study medication?  
 
Never/rarely  
Once in a while  
Sometimes  
Usually  
All the time  
 
In the last week, how many doses of study medication did you skip or forget t o take?  
 
0  
1-4  
5-10  
11-20  
21+ 
 
 
Number  of Tablets Dispensed at Last Visit : _______ __ 
 
Days Prescribed ZERO Pills Per Day : ________________________  
 
Days Prescribed ONE Pill Per Day : _____________________  
 
Days Prescribed TWO Pills Per Day : _____ ________________  
 
Total N umber of Tablets Expected to Be T aken: ________ ________________  
 
Number of Days Previous Visit  Drug was in U se: __ __________________________  
 
Did the Patient R eturn Study Medication from P rior Visit?     Yes            No 
 
If yes, date received by study team:  _______________________  
 
Number of Tablets Returned by Patient: __ _______________ __ 
 
Number of Pills Taken : _________________________________  
 
Percent Compliance: __________________________________  
 
Since the Last V isit, was the Medication O rdered to be Stopped?       Yes      No 
Date Study Medication was Stopped: __________________________  Automated 
Calculation  Automated 
Calculation  
v v Automated 
Calculation  v 
Automated 
Calculation  
v v v 
v 
v 
v 
v 
v 
v 
v 
v 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
88(91) What was the Reason for Stopping the Study Medication?   
Intolerance/side effects  
Planned medical/surgical procedure  
Partici pant non -compliance with protocol  
Other (specify)   
If other, specify: ____________________________________ __ 
 
Has Study Medication Been Restarted?    Yes  No 
If yes, date study medication was r estarted: ______________________  
Stop Ordered  by:_____________ ____________________________________  
 
Since the L ast Visit, was the Study M edication Ordered to be Reduced?  
Yes    No 
 
Date Study Medication was R educed: __________________________  
 
What was the Reason for Reducing the Study M edication ? 
Intolerance/si de effects  
Planned medical/surgical procedure  
Participant non -compliance with protocol  
Other (specify)  
If other, specify:  
__________________________________________ ___ 
Has S tudy Medication Been Increased ?   Yes  No 
 
If yes, date study medication increa sed: ________________________  
 
Change O rdered by: _________________________ ___________________  
 
 
Comments :  
 
 
Medication Compliance Completed by: _ ____________ _______  Date: ___________  v 
v 
v 
v 
v 
v 
v v 
v 
v 
v v 
v v 
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
89(91) DAPA -CAN  Payment Form  
 
Subject ID: ________________________   
Visit Date : _____________________  
Visit: ________   
Amount Owed: $___________  
 Describe Reason for Amount: _____________________________________________  
 
Participant Payment HSIP #: ___________________  
  
Check that Patient Has Been Paid  
  Date Participant was Paid: _____________________  
 
Comments:  
 
 
 
 
 
 
 
 
 
Signature of Study Team Member: ___________________________ Date: _______________  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
90(91) 
Completion  Data 
 
Subject ID:    
Is this a Screen Fail?  Yes No 
Has the  Patient  Completed the  Study?  Yes No 
Date  of Study  Completion:  N/A 
Date  Patient  Withdrew  from/Stopped  the Study:   N/A 
Reason  Patient  Withdrew  from/Stopped  the Study:  N/A 
Non-compliance  
 
Did not wish to continue  in study  
Could  not tolerate  the supplement  
Hospitalization  
Other  
If Other, Explain:     
 
Date  of Last Visit:  
 
 
 
Comments:    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Completed  By: Date:     
 
 
 
 
 
 
 
 
UM IRBMED# HUM00121107  
Clinical Study Protocol  
Drug Substance Dapagliflozin  
 
91(91)  